
HOST-PATHOGEN INTERACTIONS IN HUMANS

MECHANISMS, IMPLICATIONS, AND THERAPEUTIC STRATEGIES



Editors:
Shruti Mishra
Rupesh Chaturvedi
Achyut Pandey

Bentham Books

Host-Pathogen Interactions in Humans: Mechanisms, Implications, and Therapeutic Strategies

Edited by

Shruti Mishra
School of Biosciences and Technology, Galgotias University
Greater Noida 203201, Uttar Pradesh, India

Rupesh Chaturvedi
School of Biotechnology
Jawaharlal Nehru University (JNU)
New Delhi 110067, India

&

Achyut Pandey
School of Biosciences and Technology, Galgotias University
Greater Noida 203201, Uttar Pradesh, India

Host-Pathogen Interactions in Humans: Mechanisms, Implications, and Therapeutic Strategies

Editors: Shruti Mishra, Rupesh Chaturvedi & Achyut Pandey

ISBN (Online): 979-8-89881-810-4

ISBN (Print): 979-8-89881-811-1

ISBN (Paperback): 979-8-89881-812-8

© 2026, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore, in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2026.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (**"Work"**). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.
No. 9 Raffles Place
Office No. 26-01
Singapore 048619
Singapore
Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD i

PREFACE ii

LIST OF CONTRIBUTORS iii

CHAPTER 1 INTRODUCTION TO HOST-PATHOGEN INTERACTIONS 1

Swastick Bisht, Roshni Mishra and *Shruti Mishra*

INTRODUCTION 1

Host Environment 3

Host Environment and Lymphoid Architecture 3

Role of Microenvironment 3

INNATE IMMUNITY: IMMEDIATE DEFENCE 4

Soluble Mediators 4

Main Features of Innate Immunity 5

ADAPTIVE IMMUNITY: SPECIFICITY AND MEMORY 6

T Lymphocytes and Cell-Mediated Immunity 6

Antigen Presentation and Immunological Memory 6

Immune Modulation and Homeostasis 7

IMMUNITY AND HOST ENVIRONMENT IN HEALTH AND DISEASE 7

Pathogens 8

Features of Pathogens 8

Mechanisms of Pathogenesis 9

UNDERSTANDING PATHOGENS: BACTERIA, VIRUSES, FUNGI, AND PARASITES 10

Bacteria 10

Viruses 11

Parasites 12

Fungi 12

HOST DEFENCE MECHANISM 13

Innate Immunity 13

Adaptive Immunity 14

THE INTERPLAY BETWEEN INNATE AND ADAPTIVE IMMUNITY 14

CONCLUSION 15

REFERENCES 16

CHAPTER 2 CELLULAR AND MOLECULAR MECHANISM OF HOST DEFENSE 20

Poonam P. Ghate, Deepak Khobragade, D. Suja Rani and *Anjitha Anil Pillai*

INTRODUCTION 21

Cellular Mechanism of Host Defense System 21

Chemical barriers 22

Cellular Defense 23

Adaptive Immunity 24

Complement System 26

Molecular Mechanism of the Host Defense System 27

Immunological Memory 30

Memory B and T Cells: Long-Term Protection 31

Memory T Cells 31

Memory B Cells 31

Vaccine-Induced Immunity 31

CONCLUSION 32

REFERENCES 33

CHAPTER 3 PATHOGEN INVASION AND HUMAN HOST EVASION STRATEGIES 39
Swastick Bisht and *Shruti Mishra*
INTRODUCTION 39
PATHOGEN INVASION AS A DYNAMIC MULTISTAGE PROCESS 41
IMMUNE EVASION AS A CENTRAL DETERMINANT OF PATHOGENIC SUCCESS 43
EXPLOITATION OF IMMUNE REGULATION AND HOST TOLERANCE 46
HOST COUNTER-EVASION STRATEGIES AND IMMUNE ADAPTABILITY 48
ROUTES OF ENTRY AND CONTEXT-SPECIFIC EVASION 49
THERAPEUTIC AND VACCINE IMPLICATIONS 50
CONCLUSION 51
REFERENCES 51

CHAPTER 4 BACTERIAL-PATHOGEN INTERACTIONS WITH THE HUMAN HOST 54
Shyam Tripathi, Kusum Rani, Diksha Dahiya, Sheetal Kundu, Meher Rizvi and *V. Samuel Raj*
INTRODUCTION 55
MECHANISMS OF PATHOGEN INVASION 56
Overcoming Protective Barriers 57
Adhesion and Colonization Strategies 58
Disruption of Immune Signaling 59
HOST IMMUNE RESPONSES TO BACTERIAL PATHOGEN INTERACTIONS 60
Innate Immune Mechanisms 60
Adaptive Immune Responses 60
Role of Cytokines and Signaling Molecules 61
PATHOGEN EVASION STRATEGIES 62
Resistance to Phagocytosis 62
Toxin Production and Immune Modulation 62
Exploitation of Autophagy 63
INTERPLAY BETWEEN HOST AND PATHOGEN 64
Dynamic Interactions at Different Infection Stages 64
Pathogen Entry 64
COMMUNICATION MECHANISMS AND MOLECULAR CROSSTALK 67
PAMPs and PRRs 67
Cytokine Signaling 67
Pathogen Exploitation of Host Signaling 68
IMPACT OF THE MICROBIOTA 68
Role of Commensal Bacteria in Infection Dynamics 69
Colonization resistance 69
Modulation of the Immune System 69
Metabolic Functions 70
Dysbiosis and Its Consequences 70
Effect on Immune Function 70
Disease Association 70
Therapeutic Implications 71
FUTURE DIRECTIONS 71
Current Knowledge Gaps 71
Complexity of Microbiome 71
Pathogen-Host Interactions 72
Antimicrobial Resistance Mechanisms 72
Emerging Innovations and Techniques 72
Whole Genome Sequencing 72

Metagenomics and metatranscriptomics 72
Synthetic Biology 73
Advanced Imaging Techniques 73
CONCLUSION 73
LIST OF ABBREVIATIONS 74
REFERENCES 74

CHAPTER 5 VIRAL PATHOGEN INTERACTION WITH THE HUMAN HOST 81
Arun MT and *Aneesh Nair*
INTRODUCTION 81
Endocytic pathway of infection 84
Entry into Host Cell 85
Viral endocytosis 89
Clathrin-Mediated Endocytosis 89
Vesicular Stomatitis Virus and Clathrin-Mediated Endocytosis 90
Clathrin- and Caveolin-Independent Endocytosis 90
Caveolar Endocytosis 91
Virus-Triggered Macropinocytosis 92
Other Endocytic Pathways 92
Intracellular trafficking of the nuclear import 93
CONCLUSION 95
REFERENCES 95

CHAPTER 6 FUNGAL AND PARASITIC INFECTIONS IN HUMANS 100
Rajesh Yadav
FUNGAL INFECTION: INTRODUCTION 101
SUPERFICIAL INFECTION 102
Athlete's foot 102
Ringworm 103
Body Ringworm (Tinea Corporis) 103
Scalp Ringworm (Tinea Capitis): 103
Beard Ringworm (Tinea Barbae): 103
Hand Ringworm (Tinea Manuum): 104
Jock itch (Tinea cruris): 104
TREATMENT OF SUPERFICIAL INFECTION 105
SUBCUTANEOUS INFECTION 106
Chromoblastomycosis (CBM) 106
SYSTEMIC INFECTION 107
OPPORTUNISTIC INFECTION 107
Candidiasis 107
Aspergillosis 108
Zygomycosis 108
Cryptococcosis 108
Phaeohyphomycosis 108
Hyalohyphomycosis 108
DIAGNOSIS OF FUNGUS INFECTION IN HUMANS 109
Biopsies 109
Body Fluid Test 109
Serological Test 109
Imaging and molecular Test 110
Traditional treatment 110
Novel Antifungal Therapies 110

PARASITIC INFECTIONS IN HUMAN 111
CLASSIFICATION OF PARASITES 112
Protozoan Parasites and Diseases 113
Plasmodium Falciparum 113
HELMINTHS AND DISEASE 115
Major Groups of Helminths 115
Schistosomiasis 116
DIAGNOSING PARASITIC INFECTIONS 118
How Helminths Cause Disease 118
Transmission 118
TREATMENT 118
Common Anthelminthic Medications 118
CONCLUSION 119
REFERENCES 119

CHAPTER 7 CHRONIC INFECTION AND HOST-PATHOGEN COEVOLUTION 126
Rajesh Yadav
INTRODUCTION 126
Host-Pathogen Coevolution 127
Selective Pressures 127
Genetic Variation 127
Evolutionary Arms Race and Resistance 128
Role of Population on Host–Pathogen Coevolution 128
KAPOSI SARCOMA 128
Mechanism of Coevolution of Human and Kaposi Sarcoma-associated Herpesvirus 129
Molecular Piracy 130
The Latency-Lytic Balance 130
Disruption of Coevolution 130
Geographic and Genetic Diversification 131
Classification of Kaposi Sarcoma 131
HEPATITIS B VIRUS 132
Coevolution mechanism of host-pathogen in hepatitis B infection 133
Deep Evolutionary Origins 133
The Stealth Virus Strategy 133
Host Adaptation: The Genetic Arms Race 134
Disruption of the Balance 134
CHRONIC VIRAL INFECTIONS: HIV (HUMAN IMMUNODEFICIENCY VIRUS) 134
HIV and AIDS 135
Host-Pathogen Coevoluton in HIV Infection in Humans 136
The Cellular Arms Race: Vpu vs. Tetherin 136
Intra-Host Evolution: Escape from T-cells 137
The Mechanism of CTL Recognition and Viral Evasion 137
Host Resistance: The CCR5-delta32 Mutation 137
The HLA "Arms Race" 137
CHRONIC VIRAL-ASSOCIATED NEUROLOGICAL DISEASE 138
CHRONIC DIARRHEA 140
The Evolutionary Trade-Off: Fluid Loss vs. Persistence 140
CHRONIC KIDNEY DISEASE 141
Viral Integration and the Second Hit Hypothesis 141
CHRONIC RESPIRATORY COMPLICATIONS 142
The Trojan Horse Strategy: Alveolar Macrophages 142

CONCLUSION 142
REFERENCES 143

CHAPTER 8 INFLAMMATORY RESPONSES AND IMMUNE PATHOLOGIES 149
Palnati Nandini Reddy, Kalaivani M Kuppusamy, Prasanna Raja and *Ramanaiah Illuri*
INTRODUCTION 150
Acute Inflammation 151
Vascular Phase 151
Cellular Phase 151
Chronic Inflammation 154
Inflammatory Markers 156
Interleukins (ILs) 156
Tumor Necrosis Factor-alpha (TNF-α) 158
Procalcitonin (PCT) 159
Fibrinogen 159
Inflammatory Response to Bacteria 160
Inflammatory response to the virus 162
Cytokine Storm 163
Inflammatory Response to Cancer 165
Inflammatory Response in Autoimmune Disorders 166
CONCLUSION 169
REFERENCES 169

CHAPTER 9 THE MICROBIOME'S ROLE IN HOST-PATHOGEN INTERACTIONS 175
Priyanka Gautam, Rahul Yadav, Chandan Singh and *Abhishek Pathak*
INTRODUCTION 176
Microbiome Definition and Importance for Human Health 176
RECOGNIZING THE INTRICACY OF HOST-PATHOGEN RELATIONSHIPS 177
Significance of Comprehending the Role of the Microbiome in these Interactions 178
The Microbiome as a Layer of Protection 179
Microbiome Diversity Across the Human Body: Significant Communities and their Niches 180
Colonization Resistance: The Host is Protected by the Microbiome 181
MICROBIOME-MEDIATED MODULATION OF THE IMMUNE SYSTEM 182
Immune System Education: How Innate and Adaptive Immunity Influence the Microbiome 183
Shaping Innate Immunity 183
Shaping Adaptive Immunity 184
Metabolic and Immune Modulation 184
Clinical Implications 185
Innate Immune Crosstalk 185
Adaptive Immune Crosstalk 185
Clinical Implications 186
Priming and Tolerance: Microbiome-Mediated Immune Calibration 186
Priming: Educating the Immune System for Defense 186
Tolerance: Preventing Overreaction and Maintaining Balance 187
Examples of Microbiome-Driven Priming and Tolerance 187
Clinical Implications and Therapeutic Applications 188
The Microbiome's role in Calibrating Immune Responses to Pathogens 188
The Microbiome's Function in Adjusting Immune Responses 188
Development of Immune Cells 189
Pathogen Recognition and Immune Calibration 189
Modulation of Inflammation 190

Dysbiosis and Immune Dysregulation 190
Therapeutic Implications 190
Connection between Infection Susceptibility and Microbiota Imbalance 191
Barrier Dysfunction and Metabolic Impairment 191
Innate and Adaptive Immune Disruption 191
INTERACTIONS BETWEEN THE MICROBIOME AND SPECIFIC PATHOGENS 192
Gut Microbiome and Enteric Pathogens 193
Salmonella, Escherichia coli, and Clostridioides difficile 193
Respiratory Microbiome and Respiratory Pathogens 193
Skin Microbiome and Cutaneous Pathogens 194
Staphylococcus aureus and its Relation with Commensal Bacteria 194
Opportunistic Infections 194
Microbiome Influence on Pathogen Susceptibility in Immunocompromised Hosts 195
Pathogen-microbiome Interactions at different Body Locations 195
Gut Microbiome and Enteric Pathogens 195
Respiratory Microbiome and Respiratory Pathogens 195
Skin Microbiome and Cutaneous Pathogens 195
Fungal Infections and the Microbiome in Immunocompromised Hosts 196
MICROBIOME-PATHOGEN CO-EVOLUTION: A DYNAMIC INTERPLAY 196
Mechanisms of Microbiome-pathogen Co-evolution 197
Influence of the Microbiome on Pathogen Virulence and Evolution 198
The Role of the Microbiome in the Emergence of Antibiotic Resistance 199
THERAPEUTIC POTENTIAL OF MICROBIOME MODULATION 200
Prebiotics, Probiotics, and Postbiotics: Re-establishing Microbial Equilibrium 200
Developments in Faecal Microbiota Transplantation (FMT) 200
Engineered Microbiomes and Synthetic Consortia 201
Bacteriophages and Engineered Bacteria 201
Enhancing Vaccine Efficacy through Microbiome Modulation 202
Future Directions and Emerging Technologies 202
Microbiome Manipulation in Precision Medicine 203
Challenges in Clinical Translation 203
CONCLUSION 204
REFERENCES 204

CHAPTER 10 DEVELOPMENT OF ANTIMICROBIAL THERAPIES 214
Vandana Kumari, Kalpana Singh, Ankita Sharma and *Pratibha Singh*
INTRODUCTION 215
TRADITIONAL ANTIMICROBIAL THERAPIES 216
Mechanism of Action of Antibiotics 218
Interacting with the Bacterial Cell Wall and Interfering with its Synthesis 218
Disrupting the Biosynthesis of Bacterial Protein 218
Restricting the Synthesis of Bacterial Nucleic Acids 219
Hindering Metabolic Pathways 219
Obstructing Bacterial Membrane Function 219
Mechanism of Antibiotic Resistance 219
(a). Limiting Drug Uptake 220
(b). Drug Efflux 220
(c). Drug Inactivation 220
(d). Drug Target Modification 220
MODERN APPROACHES IN ANTIMICROBIAL THERAPIES 220
Antimicrobial Peptides 222

Nanomaterial-based Drug Delivery 224
Biomaterial-based Drug Delivery Systems 229
Role of Bioinformatics in Antimicrobial Discovery 230
Modern Applications of Antimicrobial Therapies 233
CONCLUSION 239
REFERENCES 239

CHAPTER 11 ADVANCES IN VACCINE DEVELOPMENT 246
Bhumika Singh, Supriya Pal, Shruti Nirwal and *Savitri Tiwari*
INTRODUCTION 246
STRUCTURE-BASED CATEGORIES OF VLPS 247
Non-Enveloped VLPs 247
Enveloped VLPs 248
Immune Activation Mechanisms 249
EXPRESSION FOR THE PRODUCTION OF VLP 250
Bacteria 250
Yeast 252
Insect Cells 252
Mammalian and Avian Cells 252
DEVELOPMENT AND PURIFICATION OF VIRUS-LIKE PARTICLE VACCINES 253
HPV VLP-Based Vaccine Development and Production 253
Enterovirus 71 (EV71) VLP Vaccine Production 253
Norwalk virus VLP vaccine production 254
Human Parvovirus VLP Vaccine Production 254
Influenza VLP vaccine production 254
Rotavirus VLP Vaccines Production 255
COMPARISON OF MAJOR PLATFORMS BEYOND VIRUS-LIKE PARTICLE VACCINES 255
mRNA Vaccines 255
Advantages 256
DNA Vaccines 256
Protein Subunit Vaccines 256
Peptide-based vaccines 257
Nanoparticle-Based Vaccines 257
FUTURE PROSPECTS 257
CONCLUSION 259
REFERENCES 259

CHAPTER 12 IMMUNOTHERAPY AND IMMUNE MODULATION 263
Sacheen Kumar and *Achyut Pandey*
INTRODUCTION 264
Innate Immune Responses in Host-Pathogen Interactions 264
Adaptive Immune Responses in Host-Pathogen Interactions 265
Mechanisms of Immune Evasion by Pathogens 267
Immune Evasion by Bacteria 268
Immune Evasion by Viruses 269
Immune Evasion by Fungi 271
Immune Evasion by Parasites 273
Immunotherapeutic Approaches in Infectious Diseases 275
Monoclonal Antibody Therapy 275
Immune Checkpoint Inhibitors 278
Cytokine and Immune Modulator Therapies 280

Adoptive Cell Therapies 283
Immune Modulation Strategies (Vaccines and Host-Directed Therapies) 286
Vaccines (Prophylactic and Therapeutic) 286
Host-Directed Therapies and Immunomodulatory Drugs 288
Challenges in Targeting Immune Responses Across Pathogens 290
CONCLUSION 292
REFERENCES 292

CHAPTER 13 HOST-PATHOGEN INTERACTION IN EMERGING INFECTIOUS DISEASES 301
Tarun Kumar Upadhyay and *Adil Ali*
INTRODUCTION 301
Interactions between Hosts and Pathogens 303
Understanding the Dynamics of Host-pathogen Interaction 304
Function of Macrophages in Interactions between Host and Pathogens 306
Formation of Biofilms 308
Pathogen-induced Apoptosis and Immune Evasion 309
Intracellular Microorganisms Modulate Apoptosis 309
Modulation of Extracellular Signals 310
Modulation of Signalling Pathways 311
Regulation by Disrupting Caspase Activity 312
Therapeutic Strategies to Tackle Pathogen-induced Infections 312
Virulence Factors: Core Mediator Molecules for Pathogenesis 314
Disarming the Pathogen through Neutralising the Virulence Factors 314
Disarming the Pathogen by Blocking Epithelial Adherence 314
Disarming the Pathogens through Monoclonal Antibodies 315
Disarming the Pathogens through the Neutralisation of Toxins 315
Disarming the Pathogens by Debilitating the VF Gene Expression 316
Disarming the Pathogen by Interfering with Quorum Sensing (QS) 316
Neutralising the Pathogen by Enhancing the Phagocytic Cells' ability to Kill Bacteria 317
Disarming the Pathogens by Manipulating Cytokines and Chemokines 317
Disarming the Pathogen by Targeting Immunomodulatory Peptides 318
Host-Pathogen Interaction in Emerging ssRNA Viral Infections 318
Challenges and Future Aspects 320
CONCLUSION 320
REFERENCES 321

CHAPTER 14 ARTIFICIAL INTELLIGENCE IN HOST-PATHOGEN INTERACTION 330
Shreya Mishra, Sacheen Kumar and *Achyut Pandey*
INTRODUCTION 330
AI Techniques in Host-Pathogen Interactions 332
Graph-Based AI for Protein-Protein Interactions 332
Reinforcement Learning for Drug Discovery 334
Generative Adversarial Networks for Data Augmentation 335
Federated Learning for Decentralized Data 336
Applications of AI in Host-Pathogen Research 337
Predicting Pathogen Behavior and Evolution 337
Understanding Host Immune Response 339
AI-Driven Diagnostics and Biomarker Discovery 341
Drug Discovery and Vaccine Development Using AI 343
Epidemiological Surveillance and Outbreak Prediction 346
Personalized Medicine and Treatment Strategies 349

AI in Antimicrobial Resistance Prediction 351
AI for Vector-Borne Disease Control 354
AI in Host-Pathogen Network Analysis 355
Challenges and Limitations of AI in Host-Pathogen Applications 357
FUTURE DIRECTIONS 358
CONCLUSION 359
REFERENCES 359

CHAPTER 15 FUTURE DIRECTIONS IN HOST PATHOGEN RESEARCH 366
Kajal and *Amit K. Gupta*
INTRODUCTION 366
INTEGRATION OF MULTI-OMICS APPROACHES 367
ADVANCEMENTS IN ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN HOST-PATHOGEN RESEARCH 369
DEVELOPMENT OF NOVEL EXPERIMENTAL MODELS IN HOST-PATHOGEN RESEARCH 371
Organoids, 3D Cell Cultures, and Advanced Animal Models for Studying Host-Pathogen Interactions 371
Microbiome Engineering and Its Role in Modulating Host Susceptibility 372
In vitro and In vivo Cross-Disciplinary Models for Complex Host-Pathogen Systems 372
HOST-DIRECTED THERAPEUTICS AND IMMUNOTHERAPY 374
ONE HEALTH AND GLOBAL HEALTH INITIATIVES: COLLABORATIVE APPROACHES 378
CLIMATE CHANGE AND HOST-PATHOGEN DYNAMICS 379
Coevolution and Evolutionary Pressures in Host-Pathogen Dynamics 380
EVOLUTIONARY PRESSURES ON HOSTS AND PATHOGENS 381
HOST-PATHOGEN COEVOLUTION AND VIRULENCE 381
Co-evolution and Disease Resistance 382
IMPLICATIONS FOR DISEASE CONTROL AND EVOLUTIONARY MEDICINE 382
CONCLUSION 383
LIST OF ABBREVIATIONS 383
REFERENCES 384

SUBJECT INDEX 389

FOREWORD

Understanding how our bodies respond to infections—and how pathogens try to outsmart our defenses—is at the core of fighting disease. This book brings that battle to life in a way that is both scientifically rich and deeply relevant to the world we live in today. As a physiologist, I find this subject not only fascinating but essential to how we approach health and medicine.

What stands out in this book is its ability to connect the dots—from the basic concepts of host-pathogen interactions to the latest research on immune responses and potential treatments. The contributors have done an excellent job of explaining complex ideas in a structured and engaging manner, making the content useful for everyone—from students just starting out to researchers and health professionals looking for deeper insights.

I particularly appreciate the forward-thinking approach the authors have taken. Alongside traditional topics, the book also looks ahead to new technologies like artificial intelligence that are shaping how we diagnose, study, and treat infectious diseases. This kind of vision is exactly what we need in today's fast-changing world.

My sincere congratulations to the editors and contributors for putting together such a thoughtful and timely book. I believe it will be a valuable companion for anyone interested in the science behind infection, immunity, and innovation.

Kumar Sarvottam
Department of Physiology
All India Institute of Medical Sciences (AIIMS)
Gorakhpur 273008, Uttar Pradesh, India

PREFACE

Understanding host-pathogen interactions is central to the study of infectious diseases—a field of critical importance to global health, security, and scientific progress. As editors of this volume, we are honored to present a comprehensive and timely exploration of the complex and dynamic relationships between hosts and pathogens. This book brings together cutting-edge research and expert insights to shed light on the cellular, molecular, and evolutionary mechanisms that drive these interactions.

Infectious diseases remain a persistent and evolving challenge across the world. The rise of emerging pathogens, the growing threat of antimicrobial resistance, and environmental disruptions underscore the urgent need for deeper scientific understanding. With this book, our aim is to bridge foundational knowledge with emerging perspectives. The chapters span a wide spectrum, from the basic principles of host-pathogen dynamics to the detailed mechanisms of immune responses, pathogenesis, and therapeutic strategies. We have also included forward-looking discussions on the future of the field, highlighting the role of advanced technologies, such as artificial intelligence in accelerating discovery and innovation.

This book is thoughtfully organized to serve both newcomers and seasoned researchers in microbiology, immunology, and related fields. We are deeply grateful to our contributing authors for their expertise and commitment, which have been instrumental in bringing this project to life. We also sincerely thank Galgotias University and Jawaharlal Nehru University for their support, as well as the broader scientific community whose work has laid the foundation for this effort

It is our hope that this volume not only deepens understanding but also sparks new ideas, encourages collaboration, and contributes meaningfully to the global fight against infectious diseases.

Shruti Mishra
School of Biosciences and Technology
Galgotias University, Greater Noida 203201
Uttar Pradesh, India

Rupesh Chaturvedi
School of Biotechnology
Jawaharlal Nehru University (JNU)
New Delhi 110067, India

&

Achyut Pandey
School of Biosciences and Technology
Galgotias University, Greater Noida 203201
Uttar Pradesh, India

List of Contributors

Abhishek Pathak Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, Uttar Pradesh, India

Achyut Pandey Department of Biotechnology & Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India

Adil Ali Department of Biotechnology, Parul Institute of Applied Sciences and Research and Development Cell, Parul University, Vadodara 391760, Gujarat, India

Amit K. Gupta Mouse Cancer Genetics Program, National Cancer Institute, NIH, Frederick 21702, Maryland, United States of America

Aneesh Nair Department of Allied Health Sciences, Noorul Islam Centre for Higher Education, Kanyakumari 629180, Tamil Nadu, India

Anjitha Anil Pillai MGM Silver Jubilee College of Pharmacy, Killimanoor, Thiruvananthapuram 695601, Kerala, India

Ankita Sharma Department of Textile and Fibre Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India

Arun MT Department of Allied Health Sciences, Noorul Islam Centre for Higher Education, Kanyakumari 629180, Tamil Nadu, India

Bhumika Singh Department of Life Science, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India

Chandan Singh Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, Uttar Pradesh, India

D. Suja Rani Jainee College of Pharmacy, Dindigul, Tamil Nadu, India

Deepak Khobragade Datta Meghe College of Pharmacy, Wardha, Maharashtra, India

Diksha Dahiya Department of Biotechnology, SRM University, Delhi-NCR 131029, Haryana, India
Centre for Drug Design Discovery and Development (C4D), SRM University, Delhi-NCR 131029, Haryana, India

Kajal School of Commerce, Galgotias University, Greater Noida 203201, Uttar Pradesh, India

Kalaivani M Kuppusamy Department of Biomedical Sciences, Sri Ramachandra Institute of Higher Education and Research, Chennai 600116, Tamil Nadu, India

Kalpana Singh Department of Zoology, Raja Balwant Singh College, Agra 283203, Uttar Pradesh, India

Kusum Rani Department of Biotechnology, SRM University, Delhi-NCR 131029, Haryana, India
Centre for Drug Design Discovery and Development (C4D), SRM University, Delhi-NCR 131029, Haryana, India

Meher Rizvi Department of Microbiology and Immunology, Sultan Qaboos University, Muscat 123, Oman

Palnati Nandini Reddy Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation, Krishna 521286, Andhra Pradesh, India

Poonam P. Ghate	Adarsh Institute of Pharmacy, Nagpur 440024, Maharashtra, India
Prasanna Raja	Department of Rodent Toxicology, Palamur Biosciences Private Limited, Mahabubnagar 500026, Telangana, India
Pratibha Singh	Department of Plastic, Reconstructive & Burns Surgery, All India Institute of Medical Sciences, New Delhi 110029, India
Priyanka Gautam	Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, Uttar Pradesh, India
Rahul Yadav	Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, Uttar Pradesh, India
Rajesh Yadav	Department of Physiology, Sharda School of Allied Health Sciences, Sharda University, Greater Noida 201310, Uttar Pradesh, India Department of Physiology, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India
Ramanaiah Illuri	Department of Pharmacology & Toxicology, Vidya Private Limited, Bengaluru 560078, Karnataka, India
Roshni Mishra	School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India
Sacheen Kumar	Department of Biotechnology & Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India
Savitri Tiwari	Department of Life Science, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India
Sheetal Kundu	Department of Biotechnology, SRM University, Delhi-NCR 131029, Haryana, India Centre for Drug Design Discovery and Development (C4D), SRM University, Delhi-NCR 131029, Haryana, India
Shreya Mishra	Department of Computer Science and Engineering, Indian Institute of Information Technology, Bhagalpur 813210, Bihar, India
Shruti Mishra	School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India
Shruti Nirwal	Department of Life Science, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India
Shyam Tripathi	Department of Biotechnology, SRM University, Delhi-NCR 131029, Haryana, India Centre for Drug Design Discovery and Development (C4D), SRM University, Delhi-NCR 131029, Haryana, India
Supriya Pal	Department of Life Science, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India
Swastick Bisht	School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India
Tarun Kumar Upadhyay	Department of Biotechnology, Parul Institute of Applied Sciences and Research and Development Cell, Parul University, Vadodara 391760, Gujarat, India

V. Samuel Raj Department of Biotechnology, SRM University, Delhi-NCR 131029, Haryana, India
Centre for Drug Design Discovery and Development (C4D), SRM University, Delhi-NCR 131029, Haryana, India

Vandana Kumari Department of Biotechnology, National Institute of Technology Andhra Pradesh, Tadepalligudam 534101, Andhra Pradesh, India
Department of Textile and Fibre Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India

CHAPTER 1

Introduction to Host-Pathogen Interactions

Swastick Bisht[1], Roshni Mishra[1] and **Shruti Mishra[1,*]**

[1] *School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India*

Abstract: Host–pathogen interactions are complex biological processes that determine the outcome of infectious diseases through a dynamic competition between pathogen survival and host defence. The host mounts layered protection, from physical barriers (skin and mucosa) and antimicrobial peptides to innate and adaptive immune responses that detect, contain, and eliminate invading microbes. Innate immunity provides rapid, nonspecific defence, while adaptive immunity offers highly specific, long-lasting protection via cellular and humoral components. In turn, pathogens, including bacteria, viruses, fungi, and parasites, employ diverse virulence strategies such as toxin and biofilm production, cellular hijacking, immune modulation, and antigenic variation to evade or subvert host responses. Understanding these reciprocal mechanisms, from molecular signalling (phagocytosis, cytokines, complement cascades) to immune evasion, is essential for dissecting pathogenic virulence, mapping immune dynamics, and informing rational approaches to drug development and other interventions against infectious diseases.

Keywords: Antigenic variation, Bacterial pathogenesis, Biofilms, Complement system, Cytokines, Fungal infections, Host-pathogen interaction, Immune evasion, Immunity, Mucosal immunity.

INTRODUCTION

The course of infectious diseases is shaped by dynamic interactions between hosts and pathogens, which form the foundation of host–pathogen biology. In this chapter, the major classes of pathogens, bacteria, viruses, fungi, and parasites, are examined in the context of their interactions with the host environment and the defence mechanisms that protect the host. The host provides nutrients and ecological niches for invading microorganisms, while immune recognition and neutralisation of these agents are essential for maintaining homeostasis. As the host deploys diverse defence strategies, pathogens simultaneously evolve mechanisms to access host resources, evade immunity, and establish infection.

[*] **Corresponding author Shruti Mishra:** School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India; Tel: +91-8377980804, E-mail: shrutimishra2411@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

These host–pathogen interactions are central to immunology, microbiology, and therapeutic science, making the host environment a critical arena in which pathogens either survive and adapt or are eliminated [1].

The immune system comprises two tightly interconnected arms: innate and adaptive immunity. Innate immunity constitutes the first line of defence, acting rapidly through physical barriers, phagocytic cells, and soluble mediators such as complement proteins that mediate broadly nonspecific responses. Adaptive immunity is antigen-specific and endowed with immunological memory, mediated by antigen-specific lymphocytes and antibodies that enhance pathogen clearance and provide long-term protection. Both arms must remain balanced, mounting effective responses against pathogens while avoiding excessive inflammation and autoimmunity. Pathogens are highly heterogeneous in structure, life cycle, and immune-evasion tactics; for example, many bacteria produce toxins, form biofilms, or adopt intracellular lifestyles to resist host defences [2].

Pathogenic bacteria such as Staphylococcus aureus and Escherichia coli exemplify strategies to escape immune-mediated damage, while viruses are obligate intracellular pathogens that hijack host cellular machinery for replication and spread. Viruses like HIV and influenza employ antigenic variation and interference with host signalling pathways to evade immune detection. Fungi, often opportunistic pathogens, can cause severe disease by exploiting phenotypic switching, secretion of virulence factors, and niche adaptation, as seen with Candida albicans and Aspergillus fumigatus. Parasites span unicellular protozoa and multicellular helminths; many, such as *Plasmodium* (malaria) and *Schistosoma* (schistosomiasis), modulate host immunity to establish chronic infections [3].

Host defence mechanisms are equally diverse and robust. Physical barriers, such as skin and mucous membranes, limit pathogen entry; soluble mediators, including defensins, lysozyme, and interferons, inhibit microbial growth; and phagocytic cells, such as macrophages and neutrophils, remove invaders through engulfment and killing. Lymphocytes mount highly specialised responses, guided by cytokine networks and antigen presentation, to eliminate pathogens and generate memory. This continual “arms race” between host and pathogen drives the evolution of virulence, immune strategies, and therapeutic approaches. The overview presented in this chapter highlights the host environment, the spectrum of pathogens, and the intricate defence mechanisms that maintain health. Understanding these interactions equips researchers and clinicians to confront infectious disease challenges and to design more effective preventive and therapeutic interventions [4].

At a mechanistic level, host–pathogen interactions can be conceptualised as a sequence of checkpoints: encounter, entry, sensing, effector response, and resolution or persistence. At each checkpoint, both sides deploy specialised molecules and behaviours; for example, pattern-recognition receptors on host cells that detect pathogen-associated molecular patterns, and, in turn, bacterial or viral proteins that mask or modify those patterns. Whether infection remains asymptomatic, causes acute disease, or progresses to chronic persistence depends on how these checkpoints are negotiated in specific tissues, against the background of a particular host's genetics, microbiota, age, and immune status [5].

Host Environment

The immune system allows an organism to recognize and react against pathogens, toxins, and even non-self molecules. The system is highly organized and classified into two major categories; innate immunity and adaptive immunity. Although they differ in many ways, important interactions exist between them, allowing the host to cohabit harmoniously with its commensal microbiota, forming a highly efficient system for protecting the host. Innate immunity is nonspecific but rapid; it protects promptly and encompasses mechanical barriers, immune cells, and soluble factors capable of recognizing and responding to conserved molecular patterns found on pathogens. In contrast, adaptive immunity provides both specificity and memory. Although its response time is slightly longer at initial exposure, subsequent responses are much sharper because of immunological memory [6].

Host Environment and Lymphoid Architecture

The immune system consists of specialized organs and tissues that support immune function, broadly categorized into primary lymphoid organs and secondary lymphoid organs. Primary lymphoid organs include the bone marrow, where hematopoiesis occurs and immune cells, including B lymphocytes, are produced, and the thymus, where T lymphocytes mature and are selected, thereby developing tolerance and functional competence. Secondary lymphoid organs include lymph nodes, which filter lymphatic fluid and act as sites of antigen presentation and lymphocyte activation; the spleen, which filters blood, removes pathogens and damaged cells, and is a major site of immune responses; and Mucosa-Associated Lymphoid Tissue (MALT), which includes GALT and BALT and provides a protective immune function at mucosal surfaces [7, 8].

Role of Microenvironment

The immune system operates within an enormously complex microenvironment

CHAPTER 2

Cellular and Molecular Mechanism of Host Defense

Poonam P. Ghate[1,*], Deepak Khobragade[2], D. Suja Rani[3] and **Anjitha Anil Pillai[4]**

[1] *Adarsh Institute of Pharmacy, Nagpur 440024, Maharashtra, India*

[2] *Datta Meghe College of Pharmacy, Wardha. Maharashtra, India*

[3] *Jainee College of Pharmacy, Dindigul, Tamil Nadu, India*

[4] *MGM Silver Jubilee College of Pharmacy, Killimanoor, Thiruvananthapuram, Kerala, India*

Abstract: A strong offense is the best defense, and our immune system serves as the vigilant protector of our health. The host defense systems in humans are crucial for protecting life against a variety of pathogens, including bacteria, viruses, fungi, and parasites. To eradicate invasive pathogens, the body uses a variety of defense mechanisms, including the immune system, physical barriers, and fever. These mechanisms operate in concert to create a complex web of cellular and molecular connections. This defense system comprises several organs, proteins, and cells that work together to protect the body from harmful substances. Innate, adaptive, and passive immunity are the three general categories into which the immune system is divided. At the cellular level, innate immunity is initiated when Pattern Recognition Receptors (PRRs) identify Pathogen-Associated Molecular Patterns (PAMPs), triggering responses that activate both immune and non-immune cells to recognize conserved microbial components. Inflammasomes, which are multi-protein complexes, play a critical role by activating pro-inflammatory cytokines and recruiting leukocytes to infection sites, thereby amplifying the immune response.

Adaptive immunity develops through the coordinated action of cytokines, chemokines, and lymphocytes such as B and T cells, which generate pathogen-specific responses. Additionally, antimicrobial peptides (AMPs) provide an immediate line of defence by modulating immune activity and exhibiting broad-spectrum antimicrobial effects. The complement system enhances pathogen clearance by tagging microorganisms for destruction. T cells and macrophages are central to cell-mediated immunity, offering sustained protection against intracellular pathogens and contributing to the control of chronic infections. Together, these diverse elements form a robust defence system essential for survival and underpin therapeutic strategies against infectious diseases.

[*] **Corresponding author Poonam P. Ghate:**: Adarsh Institute of Pharmacy, Nagpur 440024, Maharashtra, India; Tel: +91-9657004820, E-mail: plp.ghate@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

Keywords: Adaptive immunity, Cytokines, Complement system, Host-pathogen interaction, Immune system, Innate immunity, Inflammasomes, Pathogen-associated molecular pattern, Toll-like receptor.

INTRODUCTION

A highly developed immune system is embedded in the human body to protect against a wide range of pathogens, such as bacteria, viruses, fungi, and parasites. This defense system, composed of a complex network of cells, proteins, and organs, protects the body from infections and other harmful substances. To mount an effective defense, the immune system recognizes antigens, which are substances found on the surfaces of microbes or cells.

Focusing on the cellular and molecular mechanisms involved in detecting and eliminating infections, this chapter provides a thorough analysis of the complex host defense mechanisms in humans. It emphasizes the importance of physical barriers like the skin and mucous membranes as well as the roles of innate immune cells, such as phagocytes and natural killer cells. Also discussed are the functions of the complement system and cytokines in coordinating immune responses. The chapter concludes with a review of the key components of adaptive immunity, specifically the roles of T and B cells in the body's defense. [1].

Cellular Mechanism of Host Defense System

The immune system involves cellular mechanisms and is broadly classified into three main types: Innate, Adaptive, and Passive immunity.

- **Innate Immunity:** Innate immunity represents the body’s initial defenses, present from birth, and offers a rapid, non-specific response against invading microorganisms. This branch of immunity utilizes various strategies to block antigens, including physical barriers, chemical defenses, and cellular components that work together to prevent pathogen entry and proliferation.
- **Physical Barriers:** Skin Barrier- The skin is an essential organ of the body's innate immune system, acting as a physical barrier to protect against pathogens. It serves as a primary tough barrier to prevent entry of pathogens into the body. The epidermis, the outermost layer of the skin, is made up of tightly packed cells that prevent pathogens from entering the body. It also produces sebum, an oily substance that has antimicrobial properties, and sweat, which contains lysozyme, an enzyme that breaks down bacterial cell walls. The skin's surface is slightly acidic, which inhibits the growth of many pathogens.

- **Mucous membranes**: Mucous membranes are another essential part of the body's innate immune system. They line various cavities in the body and cover the surfaces of internal organs such as the respiratory system, digestive system, and urogenital tract, trapping pathogens. The mucous membrane contains immune cells, such as macrophages and dendritic cells, which help detect and respond to pathogens.
- **Cilia:** are hair-like arrangements in the respiratory tract that facilitate the movement of mucus to trap and expel particles from the lungs. Cilia beat in a coordinated, wave-like manner to remove particles, such as dust, bacteria, and viruses, from the respiratory tract. Cilia also help clear debris from other parts of the body, such as the Fallopian tubes in the female reproductive system [2 - 5].

Chemical barriers

These are another crucial aspect of innate immunity. Chemical barriers work along with physical barriers to provide a robust defense against pathogens. They include:

1 **Lysosomes:** Enzymes found in tears, saliva, and mucus that break down bacterial cell walls. Lysosomes in tears help prevent eye infections and wash away debris and microorganisms from the surface of the eyes, keeping them clean and protected. Saliva also contains lysosomes, which help break down bacteria in the mouth. It contains other antimicrobial proteins and enzymes that neutralize pathogens and help wash away food particles and bacteria, reducing the risk of oral infections [6].

2 **Stomach acid:** Commonly known as gastric acid, it acts as a vital part of the body's innate immune system. Many pathogens ingested with food and drink are destroyed by the highly acidic environment (pH 1.5–3.5) of the stomach. Gastric acid primarily breaks down food into simpler forms for further processing by digestive enzymes that absorb nutrients. By maintaining a low pH, stomach acid creates an intolerable environment for many microorganisms, preventing them from colonizing the digestive tract.

3 **Sebum:** Sebaceous glands in the skin produce an oily substance that has antimicrobial properties. Sebum also helps keep the skin hydrated and prevents it from becoming dry and cracked, which can create entry points for pathogens. Sebum contains fatty acids and other substances that have antimicrobial properties, helping inhibit the growth of bacteria and fungi on the skin. It forms a thin, oily layer on the skin's surface, acts as a barrier to protect against environmental damage and pathogens.

CHAPTER 3

Pathogen Invasion and Human Host Evasion Strategies

Swastick Bisht[1] and **Shruti Mishra**[1,*]

[1] *Department of Biotechnology & Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India*

Abstract: The mechanisms by which pathogens alter innate immune mechanisms, and the pathways involved in antigen presentation, effector function, and the regulation of the immune response, will receive special emphasis, with a focus on how these mechanisms create environments that allow pathogen persistence while inducing chronic inflammation. Integration of these mechanisms with concepts of host tolerance, trained immunity, and host counter-evasion provides a common framework for understanding the occurrence of paradoxical disease states characterized by vigorous immune response mechanisms with no evidence of effective immune-mediated disease resolution. The understanding of these host - pathogen interactions has direct implications for host-directed therapeutics, vaccine design, and the development of intervention strategies that target the interface between the host and the pathogen rather than simply targeting the pathogen itself.

Keywords: Chronic inflammation, Host-directed therapeutics, Immune evasion, Pathogen dissemination, Pathogen persistence, Tissue tropism, Trained immunity.

INTRODUCTION

The relationship between invading pathogens and the immune system of the human host is an ongoing evolutionary struggle that has been shaped by mutual adaptation, regulation, and counter-regulation. Throughout the course of evolution, both microorganisms and their hosts have exerted strong selective pressures upon each other, creating more advanced systems of defense in the host as well as equally complex methods of countering those defenses from the perspective of the pathogen [1]. The human immune system has developed into a multilayered and highly coordinated defense system that is able to recognize conserved signatures of pathogens, mount rapid innate immune responses, and develop highly specific adaptive immune responses. All of these immune defense

* **Corresponding author Shruti Mishra:** Department of Biotechnology & Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India; Tel: +918377980804;
E-mail: shrutimishra2411@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

mechanisms work together to control pathogen invasion, eliminate infected cells, and provide immunological memory to prevent future infections. The significant successes of many infectious agents in causing acute, chronic, and relapsing infections highlight the fact that immune detection is often inadequate for the clearance of infectious pathogens [2].

Pathogens have developed a variety of strategies by which they are able to not only traverse physical and cellular boundaries but also manipulate host immune responses. The strategies are varied and go far beyond immune evasion. The strategies include manipulation of host signaling pathways, subversion of immune effector function, and exploitation of host mechanisms regulating tissue homeostasis [3, 4]. As a consequence, infection cannot be regarded as a linear sequence of events, in which pathogens enter the body, are recognized, and are eliminated by the immune system. Rather, it should be regarded as a dynamic, bidirectional process in which pathogens and the immune system constantly adapt to one another. Thus, immune evasion cannot be regarded as a secondary factor in pathogenesis, but rather as a primary factor in pathogen survival, persistence, and transmission [5].

While the previous chapters have highlighted the various components of host immunity and specific pathogen interactions, this chapter takes a process-oriented, integrative approach. Here, the invasion and evasion of pathogens by the host are considered interconnected biological processes that occur at multiple scales. As soon as pathogens infect the host, they interact with the host's signaling mechanisms, which affect their entry, activation of the inflammatory response, and recruitment of the immune response. As infection progresses, pathogens adapt their strategies to reduce progression, lower immune activation thresholds, modify antigen presentation, and exploit immune regulatory responses, thereby facilitating persistence even in the face of a competent immune response. Such adaptive responses of pathogens result in the progression of infections from acute to chronic and to the activation of the immune response, accompanied by concurrent replication of pathogens.

It is critical to appreciate the integrated nature of pathogen invasion and host evasion to effectively grasp the paradox of infectious disease outcomes, in which strong immune responses are unable to confer sterilizing immunity but instead contribute to pathology. Chronic inflammation, immune exhaustion, and immune pathology are often a result of prolonged host-pathogen interactions, rather than immune deficiency. The conceptual framework of the chapter, which views the infectious process as a dynamic competition, serves to explain the outcomes of infectious disease, immune pathology, and therapeutic failure [6].

Ultimately, a complete understanding of the invasion and evasion process as a coupled phenomenon has significant implications for the design of effective therapies and prevention strategies. Vaccines and antimicrobials designed to combat pathogens in isolation may not be effective if the process of evasion has not been taken into consideration. Thus, this chapter aims to create a framework for integrating the strategies of pathogens and the host's immunity, and it provides critical information for the design of host-targeting therapies and vaccines [7].

PATHOGEN INVASION AS A DYNAMIC MULTISTAGE PROCESS

Pathogen invasion is a highly coordinated and sequential biological process that occurs through a series of interconnected stages, including host entry, attachment, intracellular establishment, dissemination, and, finally, transmission to new hosts. All of these stages and their specific features are depicted in Table **1**. All these stages of pathogen invasion, therefore, constitute a series of specific biological bottlenecks, each of which imposes specific selective pressures on invading pathogens, thereby influencing their adaptive strategies. Failure to successfully complete any of these stages may lead to the clearance of the pathogens, while successful completion of the entire invasion cascade may lead to persistence, chronic infection, and/or dissemination. Rather than being discrete and independent events, the various stages of pathogen invasion occur as a highly integrated process, where success in a particular stage may influence the success of the next stage. The efficiency of this entire process of pathogen invasion, therefore, determines whether infection is cleared, remains localized, or becomes a long-term and/or disseminated infection [8].

Table 1. Stages of Pathogen Invasion.

Stage of invasion	Key processes
Host entry	Contact with host surfaces *via* specific routes (respiratory, gastrointestinal, cutaneous, *etc*).
Attachment	Adhesins, glycoproteins, or pili bind specific host receptors, determining tissue tropism.
Barrier breach	Enzymes degrade extracellular matrix, disrupt junctions, or use transcellular/endocytic routes.
Intracellular survival	Avoid phagolysosomal killing, remodel intracellular niches, reprogram host metabolism.
Dissemination	Spread from the primary site using host cells or low-level replication while avoiding strong immunity.
Transmission	Exit and passage to new hosts once sufficient replication and survival are achieved.

CHAPTER 4

Bacterial-Pathogen Interactions with the Human Host

Shyam Tripathi[1,2], Kusum Rani[1,2], Diksha Dahiya[1,2], Sheetal Kundu[1,2], Meher Rizvi[3] and **V. Samuel Raj[1,2,*]**

[1] *Department of Biotechnology, SRM University, Delhi-NCR 131029, Haryana, India*

[2] *Centre for Drug Design Discovery and Development (C4D), SRM University, Delhi-NCR 131029, Haryana, India*

[3] *Department of Microbiology and Immunology, Sultan Qaboos University, Muscat 123, Oman*

Abstract: Microbial pathogens have a dynamic interplay with the human host and thus create a significant interface that needs to be appreciated in infectious diseases. It provides an all-inclusive overview of host-pathogen interactions, highlighting their value to the study of infectious diseases. It starts by discussing the concepts that underpin these interactions and underscores their importance in developing plans for therapeutic applications. Pathogen invasion mechanisms involve thebreaching of protective barriers and the use of multiple adhesions and colonization strategies. Host immune response, including innate and adaptive immunity, helps understand recognition and mechanisms of combating infections. Cytokines and signaling molecules play key roles in mediating these immunity responses. Pathogen evasion strategies will be key survival and proliferation methods within their host. This chapter will detail how pathogens avoid phagocytosis, produce toxins, and exploit cellular processes such as autophagy to avoid immune detection. The host-pathogen interaction is dynamic at all stages of infection and includes mechanisms for molecular crosstalk. Considerations are made for how the microbiota influences infection dynamics. Focus areas would include understanding the role of commensal bacteria, the implications of their dysbiosis, and the therapeutic implications of targeting virulence factors through immunomodulatory means in treatment. This provides avenues for future research directions where present-day knowledge gaps and emerging technologies to build new approaches for understanding host-pathogen interactions are identified. At the end, the chapter emphasizes the major insights gained from studying these kinds of interactions and how important they are to public health. The analysis of these dynamics helps develop novel therapies and informs preventive measures against infectious diseases.

Keywords : Bacterial pathogens, Human-host interactions, Host immune responses, Immunity, Microbiota.

[*] **Corresponding author V. Samuel Raj:** Department of Biotechnology, SRM University, Delhi-NCR 131029, Haryana, India and Centre for Drug Design Discovery and Development (C4D), SRM University, Delhi-NCR 131029, Haryana, India; Tel: +91-7082000112; E-mail: vsamuelraj22@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

INTRODUCTION

The interaction between bacterial pathogens and the human host is one of the significant research areas in infectious disease science [1]. Such interplay affects microbial survival and has major effects on the host's health. Thus, these interactions form a key base for the formulation of appropriate therapeutic strategies against bacterial infections [2]. Bacterial pathogens utilize various strategies to penetrate host tissues, circumventing the physical barriers, including the skin and mucosal surfaces [3]. They adhere using specific adhesion strategies to become established in biofilms, which can shield them from immune responses and antibiotics [4]. After establishment, the pathogens employ a range of evasion mechanisms that are used to influence the host immune response to support their survival [5]. This response of the immune system to a bacterial infection is multifaceted and involves both innate and adaptive mechanisms [6]. Innate mechanisms, being the first line of defense, prevent bacterial invasion with physical barriers, inflammatory responses, and phagocytic cells [7]. If the defense mechanisms above prove to be weak, the adaptive immune system steps in with a more specific and longer-lasting response through B and T cells [6, 8].

In addition, it is quite important to ensure that the interaction between cytokines and signaling molecules coordinates the activities of the immunity system [9]. They interact with each immune cell and, in turn, balance the severity of the response to reduce unnecessary tissue damage [10]. This means, essentially, that information on the interplay between bacterial pathogens and their human host will highlight their importance in public health. Such a way can make insights from studying host-pathogen interactions guide which path may be needed as future directions or therapeutic approaches to adequately battle bacterial infections [11].

Understanding host-pathogen interactions can help identify efficient therapeutic interventions for bacterial infections. Recent studies suggest the role of the microbiota in modulating host immune responses. A balanced microbiota will, on the one hand, facilitate host defense mechanisms and prevent overgrowth by pathogenic populations, with direct implications for modulating susceptibility to infection and determining host health, at least in part through inflammation and tolerance of the immune system. More importantly, emerging studies show that certain microbial communities can produce metabolites that enhance or inhibit the virulence of pathogens, thereby influencing disease outcomes. The more we look into these intricate relationships, the more we realize that by exploiting our knowledge of the microbiota, novel strategies for the prevention and treatment of bacterial infections can be developed, with a focus on a holistic approach to health that encompasses both microbial and immune factors [11].

MECHANISMS OF PATHOGEN INVASION

Pathogenic invasion is the mechanism by which pathogenic organisms infiltrate their hosts, establish infection, and evade host immune responses [12]. Such invasion processes have been mainly subdivided into mechanisms such as overcoming protective barriers, adhesion, colonization, intracellular invasion techniques, and evasion of immune responses (Fig. **1**) [13]. The success of pathogenic microbes thus depends on one or several mechanisms [14], as shown in Table **1**.




Fig. (1). Pictorial representation of mechanisms of pathogen invasion.

CHAPTER 5

Viral Pathogen Interaction with the Human Host

Arun MT[1] and **Aneesh Nair**[1,*]

[1] *Department of Allied Health Sciences, Noorul Islam Centre for Higher Education, Kanyakumari 629180, Tamil Nadu, India*

Abstract: Viruses are obligate intracellular parasites that can cause life-threatening infections in humans. Understanding the interactions between viral pathogens and their human hosts is vital for developing effective therapeutic strategies. This book chapter delves into the complex mechanisms underlying viral pathogenesis and disease progression. Initially, viruses interact with host cells through receptor-mediated entry, triggering a cascade of cellular responses that may either enhance viral replication or strengthen the host's immune response. The immune response to viral infections can be modulated by viral particles and host factors, with some viruses capable of evading the immune system to establish acute, chronic, or latent infections in the host. Notably, certain viruses can persist in the host for a long time without eliciting an immune response. This chapter also explores the nature of host-viral interactions, emphasizing the bidirectional influence between viruses and their specific hosts. This includes the role of host cell receptors in mediating viral entry and subsequent intracellular processes of the virus. The immune evasion tactics employed by viruses are also examined, providing insights into how viruses establish and maintain infection. The discussion extends to the impact of these interactions on disease outcomes and the development of therapeutic strategies, including vaccines and antiviral drugs. This chapter aims to enhance the understanding of viral pathogen interactions with human hosts and to provide a foundation for future research in virology and immunology.

Keywords: Antivirals, Cellular response, Complex mechanism, Disease progression, Immune system, Immune response, Intracellular parasites, Obligate parasites, Pathogenesis, Pathogens, Receptor-mediated interaction.

INTRODUCTION

Viruses, as obligate intracellular parasites, exploit host cells for replication while triggering cellular defense mechanisms [1]. The intricate relationship between viruses and host cells has fuelled advancements in both virology and cell biology, offering insights into viral life cycles and cellular responses to infection (Fig. **1**)

* **Corresponding author Aneesh Nair:** Department of Allied Health Sciences, Noorul Islam Centre for Higher Education, Kanyakumari 629180, Tamil Nadu, India; Tel; +917338861019;
E-mail: draneeshnair@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

[2, 3]. Understanding these interactions is critical for developing host-directed therapies and antivirals that target cellular components and reduce the likelihood of resistance [4, 5]. Viruses rely heavily on host pathways, from initial entry *via* receptor binding and apoptotic mimicry to uncoating, replication within specialized organelles, and eventual release [6, 7]. Recent studies have highlighted mechanisms such as apoptotic mimicry by the chikungunya virus [8], Nipah virus replication in receptor-deficient cells [9], and the role of cellular factors such as HDAC6 [10] and transportin 1 [11] in viral uncoating. These findings provide avenues for therapeutic interventions targeting these host-virus interactions.




Fig. (1). Animal viruses enter the host in stages. Animal viruses enter cells through a sequence of events that begins with the virus attaching to the cell surface, which triggers signalling pathways, causes the virus to change its shape, or facilitates endocytic internalization.

Additionally, the interplay between viruses, the immune system, and other pathogens shapes disease outcomes [12, 13]. Neutrophils can both mitigate and exacerbate arbovirus infections, as seen in Zika and Dengue [14, 15]. Co-

infections, such as influenza with Methicillin-Resistant *Staphylococcus aureus* (MRSA), complicate pathology by disrupting host defenses and amplifying virulence factors [16, 17]. Advances in understanding RNA modifications, replication organelles, and the suppression of viral protein synthesis, as shown in studies on the Ebola virus [18], further emphasize the complexity of viral pathogenesis [19]. Collectively, these insights underscore the importance of decoding virus-host dynamics to effectively combat infections and mitigate disease progression [20, 21].

Viruses or viral capsids are carried to the location of genome uncoating and replication once they enter the cytosol. For the majority of DNA viruses and some RNA viruses, the replication and delivery of nucleic acids occurs inside the nucleus of the host cell and is transported *via* the nuclear pore complex [20].

Viruses encounter multiple cellular barriers during their entry and replication. The first is the glycocalyx, a dynamic layer of proteoglycans, glycolipids, and glycoproteins that varies in composition and thickness [22]. Many viruses exploit this structure by binding to oligosaccharides for their initial attachment [23]. The plasma membrane, a highly complex and responsive interface regulated by endocytic and secretory pathways, serves as the next barrier. Viruses adeptly harness the sensitivity of the plasma membrane to external signals to facilitate entry, either through direct penetration or endocytic mechanisms [24,25]. Once inside, they must traverse the dense cortical actin network and crowded cytoplasm to reach their replication sites [26]. The genomes and accessory proteins of viruses that replicate in the nucleus strategically exploit the nuclear import machinery to penetrate the nuclear envelope and overcome the last crucial barrier [27, 28].

Virus receptors are specific cell surface molecules that help viruses attach to and enter host cells. They achieve this by triggering changes in the virus structure, activating cell signalling, or directing the virus into specific pathways for internalization [29]. In contrast, attachment factors do not directly assist in entry or signalling but help concentrate the virus on the cell surface, often without being highly specific [30]. Receptors can be various molecules, including proteins, lipids, and carbohydrates, many of which perform important physiological roles unrelated to viruses [31]. Some receptors, such as integrins, are commonly used by different viruses [32].

In many cases, viruses use more than one receptor or attachment factor to enter the cell. For example, HIV-1 uses a combination of heparan sulfate proteoglycans (for attachment), CD4 Fig. (**1**) (for initial binding), and chemokine receptors (as coreceptors) to gain entry [33]. Even though the binding affinity between a virus

CHAPTER 6

Fungal and Parasitic Infections in Humans

Rajesh Yadav[1,2,*]

[1] *Department of Physiology, Sharda School of Allied Health Sciences, Sharda University, Greater Noida 201310, Uttar Pradesh, India*

[2] *Department of Physiology, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India*

Abstract: Fungal and parasitic infections, ranging from superficial skin conditions to life-threatening systemic diseases, represent a significant global health burden. This chapter provides an overview of fungus and host interaction, fungal infections, parasite-host interaction, and parasitic infections, encompassing their diverse etiologies, clinical manifestations, diagnostic approaches, and therapeutic strategies. Fungal pathogens, including yeasts and molds, exploit various entry points into the human host, resulting in a spectrum of illnesses influenced by host immunity and environmental factors. Diagnostic methods encompass microscopy, culture, and molecular techniques, enabling accurate identification of causative agents. Treatment modalities involve antifungal medications, with choices guided by the specific pathogen and infection severity. Prevention strategies focus on minimizing exposure, particularly in immunocompromised individuals.

Fungal and host interactions are dynamic relationships that can be broadly classified into different types based on the outcome for both the fungus and the host such as Commensalism, Mutualism and Parasitism while a parasite-host interaction is a type of symbiotic relationship where one organism, the parasite, lives on or inside another organism, the host, deriving benefits (such as nutrients and shelter) while causing harm to the host.

Ongoing research aims to develop novel antifungal and antiparasitic agents and improve diagnostic capabilities, addressing the challenges posed by emerging fungal and parasitic pathogens and their resistance. Parasitic infections are diseases caused by organisms that live on or within another organism (the host) and derive nourishment from or at the expense of the host. Parasites may be classified as protozoa, helminths, or ectoparasites. Protozoa are single-celled organisms, such as amoebas, *Giardia*, and *Toxoplasma*. Helminths are parasitic worms, including roundworms, tapeworms, and flukes. Ectoparasites are organisms that live on the surface of the body, such as lice, fleas, and ticks. The most common causes are 1. Contaminated food or water: Consuming food or water contaminated with parasite eggs or cysts. 2. Insect bites:

* **Corresponding author Rajesh Yadav:** Department of Physiology, Sharda School of Allied Health Sciences, Sharda University, Greater Noida 201310, Uttar Pradesh, India & Department of Physiology, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India;
E-mail: aiimsrajesh.yadav68@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

Transmission through the bites of infected insects like mosquitoes, flies, and ticks. 3. Skin contact: Direct contact with contaminated soil or surfaces. 4. Animal-to-human transmission: Contact with infected animals or their feces.

keywords: Antifungal agents, Antiparasitic agents, Fungal infection, Helminth parasite, Parasitic infection, Protozoan parasite.

FUNGAL INFECTION: INTRODUCTION

The core categories of fungus-host interactions include:

a. Commensalism, in which the fungus benefits and the host is neither significantly harmed nor helped. For instance, *Candida albicans* often resides on human mucosal surfaces as a harmless commensal.
b. Symbiosis/Mutualism, in which both the fungus and the host benefit from their interaction. A good example of mutualism is mycorrhizal associations in plants, where fungi help the plant absorb nutrients like phosphate in exchange for carbohydrates.
c. Pathogenicity/Parasitism, in which the fungus (pathogen/parasite) benefits at the expense of the host, causing damage or disease. The severity depends on the fungal virulence factors and the host's immune status. *Aspergillus fumigatus* and *Cryptococcus neoformans* are examples of important human fungal pathogens.

In this chapter, we have focused on the last category of interaction, called pathogenicity or parasitism, in which the fungus damages the host and causes disease.

Fungal infections in humans may be superficial, subcutaneous, or systemic. In superficial infection, the fungus affects the outermost layers of the skin, hair, and nails. Examples include athlete's foot, ringworm, jock itch, and yeast infections (like thrush or vaginal yeast infections). Moisture and darkness promote the development of superficial fungal infections, which can spread to various parts of the body [1]. In subcutaneous infection, the fungus affects deeper layers of the skin [2]. Examples include sporotrichosis and chromoblastomycosis, while systemic infections affect internal organs. Infections that penetrate deep within the body, known as systemic mycoses, are caused by a range of fungal organisms and are most prevalent in people with impaired immunity. Examples are histoplasmosis, coccidioidomycosis, and cryptococcosis [3].

The most common cause of fungal infection is the overgrowth of normal fungi. 1. Fungi are naturally present on the skin, but an overgrowth can occur in warm,

moist environments. 2. Weakened immune system: People with conditions like HIV/AIDS or cancer, or those taking immunosuppressant medications, are more susceptible. 3. Exposure to environmental fungi: Inhaling spores from the environment can cause some fungal infections.

Systemic antifungal therapy for superficial fungal infections may include griseofulvin, ketoconazole, or itraconazole. A diverse selection of topical antifungal medications is also used, featuring nystatin, selenium sulfide, tolnaftate, haloprogin, miconazole, clotrimazole, and sodium thiosulfate [4].

SUPERFICIAL INFECTION

Athlete's foot

Tinea pedis, commonly known as athlete's foot, is a fungal infection of the feet. It is caused by *Trichophyton rubrum* and *Trichophyton interdigitale*. It affects approximately 3% of the global population, with higher rates observed in adolescents and adults aged 16-45 years [5]. Males are more commonly affected than females. Its transmission primarily occurs through direct or indirect contact with infected individuals or contaminated surfaces. Tinea pedis may occur in several forms. The interdigital form occurs between the toes. The hyperkeratotic (moccasin-type) form is characterized by thickened skin on the soles of the feet. The vesiculobullous (inflammatory) form is characterized by the presence of blisters and inflammation. Its clinical diagnosis can be challenging. A potassium hydroxide (KOH) wet mount examination of skin scrapings is a recommended point-of-care test. Fungal culture or molecular methods can confirm the diagnosis. Superficial infections usually respond well to topical antifungal medications. Oral antifungals are typically reserved for severe cases, treatment failures, onychomycosis (nail fungus), or immunocompromised individuals.

Tinea pedis isprimarily caused by dermatophytes [6 - 9]. It is a prevalent condition, especially among adolescents and adults, and has a growing global incidence. Historically, tinea pedis was first documented in 1888 by Pellizzari [10]. Due to its contagious nature, potential for recurrence, and role as a reservoir for other dermatophytoses, tinea pedis is considered a significant public health concern.

Epidemiology and Risk Factor: The global prevalence of tinea pedis is estimated to be approximately 3% [11]. The lifetime risk can be as high as 70%. Prevalence is higher in adolescents and adults compared to prepubertal children [12 - 13]. In recent decades, there has been an increase in prevalence, potentially linked to increased recreational activities and urbanization [14]. The peak age of incidence is between 16 and 45 years [15]. Males are more commonly affected than females,

CHAPTER 7

Chronic Infection and Host-Pathogen Coevolution

Rajesh Yadav[1,2,*]

[1] *Department of Physiology, Sharda School of Allied Health Sciences, Sharda University, Greater Noida 201310, Uttar Pradesh, India*

[2] *Department of Physiology, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India*

Abstract: Chronic infections represent a persistent challenge to host health, characterized by long-term pathogen persistence for 3-6 months and sustained immune interactions. The complexity of these infections is significantly amplified by host-pathogen coinfection, in which the simultaneous presence of multiple pathogens alters the dynamics of disease progression. This chapter explores the intricate interplay between chronic infection and coinfection, highlighting the key aspects. 1. This interplay has an impact on immune response. Coinfections can lead to complex modulation of the host immune system, with pathogens potentially competing for or synergistically influencing immune resources. This altered immune landscape can result in increased susceptibility to opportunistic infections and exacerbate existing chronic conditions. 2. Direct interactions between coinfecting pathogens, including competition for resources and modulation of virulence factors, can significantly impact disease outcomes. These interactions can also affect pathogen transmission and the evolution of drug resistance. 3. Understanding the dynamics of chronic coinfections is crucial for effective diagnosis, treatment, and prevention strategies.

Keywords: Chronic infections, HIV, HPB, Kaposi sarcoma-associated herpesvirus (KSHV), Kaposi sarcoma (KS).

INTRODUCTION

Chronic infections are persistent infections that persist in the body for extended periods, often for 6 months or more [1]. Unlike acute infections, which typically resolve relatively quickly, chronic infections can cause ongoing health problems. The following are the characteristics of chronic infection. *Persistence*: The pathogen (virus, bacteria, fungus, or parasite) remains in the body despite the immune system's efforts. *Long-term Effects*: Chronic infections can lead to chronic inflammation, tissue damage, and long-term health complications [2].

* **Corresponding author Rajesh Yadav:** Department of Physiology, Sharda School of Allied Health Sciences, Sharda University, Greater Noida 201310, Uttar Pradesh, India & Department of Physiology, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India; E-mail; aiimsrajesh.yadav68@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

Variable Symptoms: Symptoms can range from mild or nonexistent to severe and may fluctuate over time. Sometimes, there are no noticeable symptoms at all. *Immune SystemInvolvement*: The immune system plays a crucial role in chronic infections, but it may not be able to eliminate the pathogen [3]. Sometimes, the immune system's responses can contribute to the damage. Examples of chronic infections include: *Viral*: HIV (human immunodeficiency virus), Hepatitis B and C, and Herpes simplex virus (HSV); *Bacterial*: Tuberculosis (TB), Lyme disease (in some cases); and*Fungal*: Certain forms of aspergillosis. *Parasitic*: Schistosomiasis

Host-Pathogen Coevolution

This refers to the reciprocal evolutionary adaptations that occur between a host and its pathogen. As the host evolves defences to combat the pathogen, the pathogen, in turn, evolves strategies to evade those defences. This creates an evolutionary arms race where both sides are constantly adapting [4], illustrating the dynamics of coevolution in chronic infections.

Selective Pressures

Chronic infections exert strong selective pressures on both the host and the pathogen. The host's immune system selects pathogen variants that can evade immune recognition. Conversely, the pathogen selects host variants that are more susceptible to infection or provide a favourable replication environment. While selection pressures generally favour pathogen traits that maximize fitness through optimized growth, reproduction, and virulence, host diversity introduces a critical complexity. A virulence level that is advantageous in one host phenotype may be detrimental in another. Consequently, pathogens can evolve diverse virulence strategies, either through polymorphism, in which specialized strains target specific hosts, or through polyphenism, in which individual pathogens adjust their virulence based on the host. Polymorphism promotes pathogen specialization, whereas polyphenism can lead to broader host ranges. Investigating the impact of host variation on virulence evolution is fundamental to understanding pathogen diversification and the reciprocal evolutionary influences between hosts and their pathogens [5].

Genetic Variation

Genetic variation in both the host and the pathogen is essential for coevolution to occur. Mutations in the pathogen's genome can lead to changes in virulence or antigenicity. Variations in the host's immune response genes can influence susceptibility to infection. Natural selection amplifies genetic variation in host susceptibility by comparing responses to familiar and unfamiliar pathogens.

Through a comprehensive cross-infection study involving four *Drosophila* species and their respective host-specific viruses, the study observed heightened genetic variability in susceptibility to coevolved viruses. Further analysis of the genetic basis of resistance in one host species revealed a greater prevalence of major-effect genetic variants in coevolved host-pathogen systems [6]. Therefore, it can be concluded that pathogen-driven selection enhances genetic variation in host susceptibility, with a significant contribution from major-effect resistance polymorphisms within host populations.

Evolutionary Arms Race and Resistance

The constant adaptation of both the host and the pathogen can lead to an evolutionary arms race, in which each side continually evolves new strategies. This can result in the emergence of new pathogen strains that are more virulent or resistant to treatment. This can also result in host populations that have increased resistance to specific pathogens [7]. It is important to understand the difference between tolerance and resistance. Resistance is the host's ability to limit the pathogen burden. Tolerance is the host's ability to limit the damage caused by the pathogen without necessarily reducing the pathogen's burden. Both of these factors play a major role in coevolution.

Role of Population on Host–Pathogen Coevolution

A population's capacity for rapid evolutionary adaptation is significantly influenced by its size. Population size dictates the introduction of new genetic variations through mutation and recombination, as well as the preservation of existing genetic diversity. Furthermore, it modulates the relative influence of natural selection versus random genetic drift. Therefore, populations with larger numbers exhibit greater evolutionary potential than those with limited sizes or those that have experienced population bottlenecks, which suffer from reduced genetic diversity and heightened genetic drift.*C. elegans* and *B. thuringiensis* were used to study coevolution in varying population sizes. Small and bottlenecked *C. elegans* populations showed limited adaptation over 23 generations. This resulted in different coevolutionary dynamics and genotype interactions compared to large populations, demonstrating that host population size strongly influences co-adaptation [8].

KAPOSI SARCOMA

Kaposi sarcoma is one of the examples of chronic infection. Kaposi Sarcoma (KS) is a malignancy that develops in individuals with chronic infection of Kaposi sarcoma-Associated Herpesvirus (KSHV), or human Herpesvirus 8 (HHV-8). The risk of Kaposi sarcoma is remarkably elevated in those with chronic HIV

CHAPTER 8

Inflammatory Responses and Immune Pathologies

Palnati Nandini Reddy[1], Kalaivani M Kuppusamy[2], Prasanna Raja[3,*] and Ramanaiah Illuri[4]

[1] *Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation, Krishna 521286, Andhra Pradesh, India*

[2] *Department of Biomedical Sciences, Sri Ramachandra Institute of Higher Education and Research, Chennai 600116, Tamil Nadu, India*

[3] *Department of Rodent Toxicology, Palamur Biosciences Private Limited, Mahabubnagar 500026, Telangana, India*

[4] *Department of Pharmacology & Toxicology, Vidya Private Limited, Bengaluru 560078, Karnataka, India*

Abstract: Inflammation is a complex biological response of the immune system to harmful stimuli, including pathogens that cause communicable disease, damaged cells, or irritants. It is an essential defense mechanism designed to protect tissues, initiate repair processes, and restore homeostasis. The inflammatory response is characterized by hallmark signs such as erythema (redness), edema (swelling), increased local temperature, pain, and occasionally loss of function. Inflammation can be classified as acute or chronic. Acute inflammation is a transient and localized response that aims to eliminate the inciting factor and promote tissue repair, whereas chronic inflammation is prolonged and may result in persistent tissue damage, fibrosis, and the progression of various pathologies, including autoimmune diseases, metabolic syndromes, and cardiovascular disorders. The inflammatory response is a tightly regulated immune process that addresses tissue injury or pathogen invasion. The inflammatory response plays a significant role in the prevention of communicable diseases caused by pathogens, involving both innate and adaptive immune systems. The inflammatory response in cancer is complex, with both tumor-promoting and tumor-suppressing effects. Understanding the interplay of inflammation in cancer progress is crucial for developing therapies that modulate the immune response to control tumor growth. In the inflammation process, cytokine storm is an excessive, uncontrolled release of pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-1β, leading to widespread inflammation and tissue damage. It is often triggered by severe infections, autoimmune diseases, and/or certain treatments. This overactive immune response causes organ failure, shock, and Acute Respiratory Distress Syndrome (ARDS). This chapter provides insight into the inflammatory response during infection, in pathological conditions, and after vaccination.

* **Corresponding author Prasanna Raja:** Department of Rodent Toxicology, Palamur Biosciences Private Limited, Mahabubnagar 500026, Telangana, India; E-mail: prasannaraja.c@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

Keywords: Anti-inflammatory cytokines, Communicable disease, Immunity, Inflammation, Pro-inflammatory cytokines.

INTRODUCTION

Inflammation is a multifaceted biological reaction of the immune system to detrimental stimuli, such as pathogens, injured cells, or irritants. It is a crucial defense mechanism intended to safeguard tissues, commence healing processes, and reestablish equilibrium. The inflammatory response is marked by key indicators like erythema, edema, elevated local temperature, discomfort, and, at times, loss of function [1]. Inflammation is categorized as acute or chronic: acute inflammation is a temporary and localized reaction intended to eradicate the triggering factor and facilitate tissue repair, while chronic inflammation is enduring and can lead to ongoing tissue damage, fibrosis, and the advancement of numerous pathologies, such as autoimmune diseases, metabolic syndromes, and cardiovascular disorders [2]. The inflammatory response is a meticulously regulated immune mechanism that responds to tissue damage or pathogen infiltration. The process initiates with the activation of Pattern Recognition Receptors (PRRs) on immune cells such as macrophages and dendritic cells, which identify molecular patterns from pathogens (Pathogen-Associated Molecular Patterns, PAMPs) or from damaged cells (Damage-Associated Molecular Patterns, DAMPs). This triggers the secretion of pro-inflammatory mediators, including cytokines (*e.g.*, IL-1β, TNF-α), chemokines, and lipid mediators [3]. These mediators facilitate vasodilation, enhance vascular permeability, and promote immune cell recruitment, enabling neutrophils and monocytes to move to the site of injury. Neutrophils execute phagocytosis, whereas monocytes differentiate into macrophages to sustain the response and facilitate tissue healing. Resolution of inflammation involves anti-inflammatory signals (*e.g.*, IL-10 and TGF-β), which inhibit further inflammation, promote clearance of immune cells, and support tissue repair. Dysregulated resolution may result in persistent inflammation, contributing to conditions such as arthritis, inflammatory bowel disease, and atherosclerosis [4]. Moreover, various biomolecules or clinical characteristics, known as inflammatory markers, indicate the presence and intensity of inflammation in the body. They are produced by numerous immune and non-immune cells in response to inflammatory stimuli and are essential for the diagnosis, prognosis, and monitoring of inflammatory disorders. Key inflammatory markers include C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), pro-inflammatory cytokines, fibrinogen, and leukocyte counts, which help elucidate the pathophysiology of inflammatory responses, guide therapeutic interventions, and assess disease progression in conditions such as rheumatoid arthritis, inflammatory bowel disease, and cardiovascular disorders [5].

Inflammation can be broadly categorized into two types: acute and chronic, each with distinct characteristics, causes, and consequences.

Acute Inflammation

Acute inflammation is the immediate and early response of the body to harmful stimuli, such as pathogens, physical trauma, or irritants. It is characterized by the rapid influx of immune cells (particularly neutrophils) to the affected site and the release of inflammatory mediators like histamine, prostaglandins, and cytokines. The classic signs of acute inflammation include redness, swelling, heat, pain, and loss of function. These symptoms result mainly from vasodilation and increased blood flow, leading to greater vascular permeability and immune cell recruitment to the affected area [6]. The primary goal of acute inflammation is to neutralize the threat and restore tissue homeostasis. In most cases, this process resolves within a few days, leading to complete healing. However, if the inflammatory response is not effectively controlled or if the injurious stimulus persists, acute inflammation can progress to chronic inflammation [6].

Acute inflammation can be described in two key phases: a vascular phase and a cellular phase.

Vascular Phase

The vascular phase of acute inflammation is characterized by a series of hemodynamic and structural alterations within the microvasculature. This phase begins with an initial, transient vasoconstriction, followed by sustained vasodilation, which increases blood flow to the affected area (hyperemia). Concurrently, the endothelial cells lining the blood vessels become activated, leading to increased vascular permeability. This allows plasma proteins, such as fibrinogen, complement components, and immunoglobulins, to exit the bloodstream and enter the interstitial tissue, where they contribute to pathogen neutralization and tissue repair [7]. Molecular mediators, including histamine, bradykinin, prostaglandins, and nitric oxide, play central roles in regulating these vascular changes. The activation of endothelial cells also facilitates leukocyte adhesion and migration through the process of diapedesis, linking the vascular and cellular phases of inflammation. Importantly, the vascular phase sets the stage for the recruitment of immune cells by creating a microenvironment conducive to pathogen clearance and healing [8].

Cellular Phase

The cellular phase of acute inflammation is characterized by the recruitment, activation, and effector functions of leukocytes, particularly neutrophils. This

CHAPTER 9

The Microbiome's Role in Host-Pathogen Interactions

Priyanka Gautam[1], Rahul Yadav[2], Chandan Singh[2] and **Abhishek Pathak[1,*]**

[1] *Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, Uttar Pradesh, India*

[2] *Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, Uttar Pradesh, India*

Abstract: The bacteria, fungi, viruses, and archaea that make up the human microbiome interact to determine how our bodies respond to infections and control our immune systems. This chapter explores the protective role of the microbiome in maintaining our health and affecting our susceptibility to infections. The microbiome supports defense against harmful pathogens and the maintenance of a healthy immune response through a variety of biochemical processes, including competitive exclusion, the synthesis of antimicrobial compounds, and immune system training. However, when dysbiosis occurs, these defenses may fail, leading to immunological problems, persistent inflammation, and an increased risk of infections. Short-Chain Fatty Acids (SCFA) and bacteriocins are examples of microbial byproducts that are critical for lowering inflammation and promoting the growth of regulatory T cells (Tregs), which are vital for controlling our immune system. Furthermore, the microbiome affects T and B cell function, which improves our capacity to withstand a variety of substances and to fight against infections. Microbes and pathogens continue to co-evolve, demonstrating a dynamic interaction that affects how diseases arise and how infections adapt to avoid treatment. We now have a better understanding of the relationships between hosts, microbiomes, and infections thanks to developments in disciplines like computational biology, genomics, proteomics, and metabolomics, opening the door to precision medicine. In order to restore microbial balance and prevent infections, therapeutic treatments such as probiotics, prebiotics, Faecal Microbiota Transplantation (FMT), and synthetic microorganisms show significant potential. Also, advances in microbiome-targeted therapeutics are being driven by multi-omics technology. This thorough comprehension of the microbiome's essential function in immune regulation shows its major effect on infection outcomes and immunological-related diseases, laying the groundwork for revolutionary developments in disease prevention and treatment approaches.

[*] **Corresponding Author Abhishek Pathak:** Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, Uttar Pradesh, India; Tel: +91-8948512666;
E-mail: abhishekpathakims@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

Keywords: Dysbiosis, Host-pathogen interaction, Immune regulation, Microbiome, Microbiome-based therapies.

INTRODUCTION

Recent breakthroughs have highlighted the importance of the microbiome in influencing how our bodies respond to infections. Beyond its many functions, the gut microbiota plays a crucial role in regulating our overall health, particularly by helping the intestinal immune system develop and by enhancing digestion. It does this by reclaiming nutrients and calories that would otherwise be lost in our waste [1, 2]. In a healthy state, the relationship between a host and its microbiota works like a well-oiled machine, keeping everything in balance. But when that balance is disrupted it can lead to chronic inflammatory diseases, highlighting how intricate the connection is between the dynamics of the microbiome and the health of the host [3, 4].

In line with the overarching themes of this book, this chapter delves into the interactions between hosts and pathogens in relation to human health. It integrates knowledge on how the microbiome affects disease processes and investigates possible treatment strategies. Examining how these microbial communities impact the host's reaction to diseases is crucial since the gastrointestinal system has the greatest number of bacteria in the human body.

Microbiome Definition and Importance for Human Health

The human microbiome is made up of many species, including bacteria, fungi, viruses, and archaea. This intricate community is essential for maintaining the equilibrium of our bodies, forming our immune systems, supporting the metabolism of nutrients, and protecting us from dangerous infections [5]. Its significance for human health becomes apparent from recent research, which demonstrates that, depending on its composition and interactions with the host, it can either increase disease resistance or, conversely, contribute to disease [6].

Numerous studies have examined changes in the microbiome in preclinical and clinical models of chronic inflammatory diseases [7]. While previous studies mostly examined the microbiome's impact on the metabolism of carbohydrates, a more recent study demonstrates the microbiome's role in preserving protein balance as well [8]. Certain beneficial bacteria, in particular, appear to help shield kids from malnutrition, suggesting that their metabolic impact goes beyond carbs.

When it comes to the breakdown of the proteins we consume, the gut microbiota is crucial. The release of tryptophan, which our bodies then transform into a variety of bioactive substances, is a crucial step in this process. Numerous health

benefits have been demonstrated for these tryptophan-derived metabolites. For example, they strengthen the intestinal barrier, improve gastrointestinal motility, boost immunity, and provide detoxifying, anti-inflammatory, and antioxidant benefits throughout the body [9, 10]. Furthermore, a variety of metabolites are produced by the complex oral microbiota found in saliva, some of which may be linked to oral sores and infections. These microbial metabolites can interact with substances that our cells secrete, forming intricate networks that scientists are increasingly investigating as potential biomarkers, particularly in severe illness. Tryptophan and other aromatic amino acids are particularly important in this context because the development of oral cancer has been linked to their metabolic byproducts [11].

RECOGNIZING THE INTRICACY OF HOST-PATHOGEN RELATIONSHIPS

The way infections develop is greatly influenced by host-pathogen interactions, which are like an ever-changing symphony. These connections can range greatly, from benign colonization with no symptoms to dangerous, fatal diseases. The core of it all is a continuous struggle between the viruses' survival strategies and the host's defenses, with each side evolving to counter the other [12].

In order to establish themselves in a host, pathogens use a number of effective strategies. They have the ability to adhere to host cells, discharge toxic substances, evade the immune system, and even seize control of the host's cellular apparatus. For example, bacteria may form protective biofilms that serve as barriers against immune responses and drugs, but viruses rely on host cells for replication [13, 14].

Hosts have evolved sophisticated immune systems over time to identify and eradicate these intruders. Pathogen-Associated Molecular Patterns (PAMPs) are recognized by the innate immune system using Pattern Recognition Receptors (PRRs), which initiate signalling cascades that activate immune cells and cause inflammation [15]. Long-term protection is improved by the adaptive immune system's addition of memory and specificity to this reaction.

Numerous factors, including host genetic variability, pathogen diversity, and environmental conditions, affect the complexity of host-pathogen interactions. For instance, variations in immune-related genes may affect an individual's susceptibility to infections. The microbiome of the host or the presence of other illnesses can also have a significant impact on how the disease progresses. However, because of recombination, mutations, and Horizontal Gene Transfer (HGT), infections are always evolving, rapidly adapting to and eluding host defenses [16, 17].

CHAPTER 10

Development of Antimicrobial Therapies

Vandana Kumari[1,2], Kalpana Singh[3], Ankita Sharma[2] and **Pratibha Singh[4,*]**

[1] *Department of Biotechnology, National Institute of Technology Andhra Pradesh, Tadepalligudam 534101, Andhra Pradesh, India*

[2] *Department of Textile and Fibre Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India*

[3] *Department of Zoology, Raja Balwant Singh College, Agra 283203, Uttar Pradesh, India*

[4] *Department of Plastic, Reconstructive & Burns Surgery, All India Institute of Medical Sciences, New Delhi 110029, India*

Abstract: The development of antimicrobial therapies has played a vital role in combating infectious diseases, particularly with the growing problem of Antimicrobial Resistance (AMR). The chapter highlights the rising challenge of AMR, in which bacteria and other microbes become resistant to existing treatments, and emphasizes the urgent need for new solutions to combat this issue. This chapter outlines the evolution of antimicrobial treatments from their early stages to the latest advancements. It covers traditional antibiotics as well as newer approaches like antimicrobial peptides, nanotechnology-based systems, and phage therapy, which uses viruses to target bacteria. Bioinformatics plays a transformative role in accelerating the discovery and optimization of antimicrobial therapies. By leveraging tools like genomics and computational models, bioinformatics helps identify novel drug targets and improve the effectiveness of existing treatments. Bioinformatics tools, such as gene sequencing and molecular docking, aid in discovering new drug targets, predicting resistance patterns, and designing customized antimicrobial agents. Recent advancements in antimicrobial peptides, nanotechnology, and biomaterials-based drug delivery systems have revolutionized the discovery and design of targeted and controlled antimicrobial therapies, offering potential against multidrug-resistant pathogens. Additionally, the chapter addresses the applications of antimicrobial therapies in the human healthcare sector, industrial applications, and the agriculture sector. By offering a comprehensive overview of current innovations and emerging trends, this chapter aims to help researchers and clinicians gain a better understanding of the future direction in the development of antimicrobial therapies.

Keywords: Antimicrobial resistance, Antimicrobial peptide, Bioinformatics, Biomaterials, Drug delivery systems, Genomic sequencing, Infection-resistant biomaterials, Nanomedicine.

[*] **Corresponding author Pratibha Singh:** Department of Plastic, Reconstructive & Burns Surgery, All India Institute of Medical Sciences, New Delhi 110029, India; E-mail: pratibhas1402@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

INTRODUCTION

The inception of time has signified the simultaneous existence of humans and infectious germs. Humanity has witnessed several epidemics, endemics, pandemics, and outbreaks throughout history. COVID-19 is one of the current illnesses that has affected people worldwide. Earlier, these diseases were referred to as "plagues" without distinction. Their descriptions were always evasive [1, 2]. The discovery of the germ theory, which encompassed tiny parasites, germs, and viruses, was a landmark. This was largely due to the work of Koch, Lister, Pasteur, and many others. The first to convincingly link an infectious disease with tiny sticks (bacteria) found in the blood of animals killed by anthrax was Davaine. Later, Koch rigorously proved their pathogenicity. Many more bacteria and viruses were rapidly recognized [1].

The most significant reduction in infectious disease mortality in the USA occurred over 15 years, from 1938 to 1952, during which the yearly mortality rate declined fast to 8.2% per year. The infectious diseases that mainly contributed to this significant drop were pneumonia, influenza, and tuberculosis. The observed declines coincided with the implementation of sulphonamides in 1935, penicillin in 1941, and streptomycin in 1943, along with various combination therapies, including para-aminosalicylic acid in 1944 and isoniazid in 1952, introduced for tuberculosis treatment alongside streptomycin. This correlation unequivocally demonstrates the significance of antimicrobials in managing infectious illnesses [3].

The discovery of antimicrobial drugs has significantly transformed both the treatment of infectious diseases and the destiny of humanity. Significant progress in antimicrobial therapy gave an optimistic vision that infectious diseases would soon be eradicated. Antibiotics have transformed medical practice by facilitating advancements in various clinical areas, including post-childbirth care, surgical interventions, organ transplantation, and myeloablative chemotherapy protocols.

Nonetheless, developing and re-emerging infectious illnesses have led to outbreaks. Infections caused by drug-resistant organisms continue to pose a significant challenge in clinical practice that is difficult to address. Infection with Antimicrobial Resistance (AMR) results in severe diseases, extended hospital stays, raised healthcare expenses, increased expenditures for second-line drugs, and treatment failures. AMR signifies the ability of bacteria and other microorganisms to resist the effects of an antibiotic to which they were before vulnerable, enabling pathogens to endure and proliferate. Conclusively, Antimicrobial Resistance (AMR) poses a significant threat to hindering, and possibly reversing, advancements in medical history [4, 5].

It is essential to understand the reasons for AMR development to tackle the threat posed by AMR. Any living entity, including microorganisms, evolves to ensure survival. They adapt according to the environment and evolve for their existence. Once exposed to antibiotics, microorganisms undergo genetic alteration for survival [6], resulting in antibiotic resistance naturally. Nonetheless, various factors continue to be involved in the complex aetiology of antibiotic resistance [7]. The factors that are associated with AMR are:

a. Emergence of Denovo mutations during bacteria replication cycles,
b. Usage of antibiotics for prophylactic, metaphylactic, and growth-promoting uses in agriculture.
c. Overuse and misuse of antibiotics in human and veterinary medicine.
d. Gap in knowledge
e. Inaccurate diagnosis and prescription of antibiotics [8].

In the United States, antimicrobial-resistant pathogens are responsible for about 2 million illnesses and are linked to approximately 23,000 fatalities annually. In Europe, Antimicrobial Resistance (AMR) is related to around 25,000 yearly fatalities. The economic burden of Antimicrobial Resistance (AMR) is significant, with annual extra medical expenditures in the United States estimated at $20 billion. The comprehensive global impact of AMR is challenging to evaluate due to the scarcity of epidemiological data in numerous regions worldwide [5, 9].

The World Health Organisation (WHO) has cautioned over the imminent threat of a pre-antibiotic era, highlighting 12 developing superbugs that exhibit resistance to numerous drugs. Approximately 40% of Staphylococcus Aureus strains in hospitals exhibit methicillin resistance, resulting in nearly 120,000 bloodstream infections and 20,000 associated fatalities in the United States in 2017. Antimicrobial resistance is responsible for around 700,000 deaths globally each year. It is projected that by 2050, it will impact 230 million individuals and lead to 10 million fatalities annually. The discovery of new classes of antimicrobials has significantly diminished since 1987, exacerbating the situation and threatening a regression to the "medical dark ages." Consequently, there is an immediate need to advance innovative alternative strategies to address the antimicrobial-resistant disease dilemma [10]. To produce new antimicrobial therapies, understanding the basics of traditional antibiotics, their mechanism of action, and their limitations is essential.

TRADITIONAL ANTIMICROBIAL THERAPIES

The name 'antibiotic' derives from the word 'antibiose,' first used as an antonym of 'symbiosis' by Paul Vuillemin in his 1890 article. It characterizes the antagonistic

CHAPTER 11

Advances in Vaccine Development

Bhumika Singh[1], Supriya Pal[1], Shruti Nirwal[1] and **Savitri Tiwari[1,*]**

[1] Department of Life Science, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India

Abstract: Many attenuated and inactivated vaccines were inadvertently reversed in the 1970s and 1980s, which resulted in the identification and creation of particles that resemble viruses (VLPs). The antigenic determinant is the only structural component of the target virus that the VLPs possess, and it may elicit immune responses comparable to those elicited by the original viruses. However, the particles cannot infect like the actual viruses because they do not contain genetic information. They can activate both humoral and cell-mediated immune responses. This technique offers a dependable and secure method of fighting infectious diseases because contamination fails to develop. VLPs have already been developed for a number of infectious disorders, and research is underway to develop VLPs for numerous others. Based on their structure, VLPs can be categorized as either enveloped or non-enveloped. Enveloped VLPs have greater flexibility. Several different expression systems can be used to create VLPs. Insect cell culture systems are primarily used for VLP production. When selecting the appropriate system, the type of VLP in question needs to beconsidered during account setup. All the VLPs are produced and purified in a very similar way: the antigenic section gene is cloned, cells are harvested, and disruption (if required), clarity, concentration, and characterization are carried out using different techniques. This chapter provides an overview of VLP classifications, their immune-stimulating characteristics, and the range of expression systems available for their production, as well as the methods used in their manufacture.

Keywords: Antigenic determinants, Dendritic cell activation, Enveloped and non-enveloped VLPs, Humoral and cell-mediated immunity, Insect cell culture systems, Recombinant vaccines, Subunit vaccines, Virus-like particles (VLPs).

INTRODUCTION

The practice of vaccination dates back to the late 1700s. Newer and more sophisticated vaccines have been developed over time. Live viruses that have been attenuated or rendered inactive serve as the basis for several vaccines against

[*] **Corresponding author Savitri Tiwari:** Department of Life Science, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India; Tel: +91-8544801819;
E-mail: savitri.tiwari@galgotiasuniversity.edu.in

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

viral illnesses. Inactivated or attenuated viruses have the potential to revert to their virulent form, which could result in a variety of severe diseases [1]. This clarifies why a number of early vaccines were at times associated with unexpected viral outbreaks, like the one brought on by the virus that causes foot-and-mouth disease (FMDV). In the 1970s, scientists revealed that a viral protein was sufficient to develop a vaccine capable of preventing such epidemics [2]. In 1981, the initial genetically modified veterinary vaccine was developed by cloning the antigenic region 'VP3' of the FMDV into *Escherichia coli* [3]. Later, the first recombinant vaccine for human use targeting the surface antigen of the hepatitis B virus (HBsAg) was developed using recombinant DNA technology [4]. The first vaccination made from Virus-Like Particles (VLPs) was the recombinant HBV vaccine; nevertheless, because it does not directly replicate the intact virion, it is not a true VLP. Subunit vaccines, or VLPs, are able to replicate the general structure of virus particles without the need for infectious genetic material. The idea behind Virus-Like Particle (VLP) preparations is that when viral capsid proteins are expressed, particles that closely mimic native viruses in structure are assembled. Thus, VLPs can trigger Cytotoxic T-Lymphocyte (CTL) and B-cell - driven immunological reactions. One of the main reasons VLPs were chosen as vaccine candidates was because of this unique quality. Notably, numerous VLPs lack the target virus's genetic material, thereby eliminating the possibility of reversion or reassortment into an infectious, virulent form [1].

STRUCTURE-BASED CATEGORIES OF VLPS

VLPs fall into two primary categories based on their structure: enveloped and non-enveloped VLPs [5].

Non-Enveloped VLPs

Non-enveloped VLPs consist of one, two, or more target components that self-assemble into particles without host-derived elements [6–7] (Fig. **1**). These VLPs are used in vaccines against parvoviruses (*e.g.*, canine, porcine, and mink parvoviruses) [8–9]. Hepatitis E Virus (HEV) VLPs, produced from truncated capsid proteins in insect cell systems (Sf-9/Tn-5), exemplify non-enveloped designs [10]. Hepatitis B surface antigen recombinant (HBsAg) VLPs are generated in yeast [11] or animal cells (with human serum albumin receptors) [12], differing in properties based on host systems and engineering [13].

Chimeric non-enveloped VLPs fuse target antigens to particle surfaces. For example:

- The malaria vaccine RTS,S combines HBsAg VLPs with the *Plasmodium* circumsporozoite protein [14].
- Plant virus coat proteins (*e.g.*, Alfalfa mosaic virus) are engineered to carry HIV-1 or rabies antigens [15].

Complex non-enveloped VLPs, such as those in the *Reoviridae* family, feature multi-layered capsid proteins [16].




Fig. (1). An example of the structural diversity of VLPs that are not enclosed (Lua *et al.*,2014).

Enveloped VLPs

Enveloped VLPs incorporate host-derived membranes displaying surface antigens, offering structural flexibility (Fig. **2**). Examples include influenza and retrovirus VLPs. Their production involves:

1. Expression of viral structural proteins
2. Particle assembly and membrane integration
3. Budding from host cells [17].

CHAPTER 12

Immunotherapy and Immune Modulation

Sacheen Kumar[1] and **Achyut Pandey**[1,*]

[1] *Department of Biotechnology & Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India*

Abstract: Infectious diseases continue to pose significant global health challenges despite advances in antimicrobial therapies, necessitating innovative approaches that leverage the host immune system. This chapter explores the evolving field of immunotherapy and immune modulation as complementary strategies to traditional treatments, focusing on their application across bacterial, viral, fungal, and parasitic infections. It begins by detailing the innate and adaptive immune responses critical to host-pathogen interactions, highlighting how pathogens employ sophisticated evasion mechanisms, such as antigenic variation, immune suppression, and intracellular concealment, to persist. The chapter then reviews current immunotherapeutic approaches, including monoclonal antibodies (*e.g.*, palivizumab for RSV, bezlotoxumab for *C. difficile*), immune checkpoint inhibitors (*e.g.*, PD-1 blockade in chronic infections), cytokine therapies (*e.g.*, IFN-γ for intracellular pathogens), and adoptive cell transfers (*e.g.*, virus-specific T cells in transplant patients). Vaccines, both prophylactic and therapeutic, are examined as foundational immune modulation tools, with recent advances like mRNA platforms and host-directed therapies (*e.g.*, metformin in TB) also discussed. Clinical trials and outcomes underscore the promise and challenges of these interventions, including balancing efficacy with immunopathology, addressing pathogen evolution, and navigating individual immune variability. The chapter concludes that immunotherapy and immune modulation, by targeting the host-pathogen interface, offer transformative potential to enhance pathogen clearance, mitigate disease severity, and improve global health outcomes when integrated with conventional treatments. Continued research is essential to refine these strategies and overcome implementation hurdles, paving the way for personalized and combination therapies in infectious disease management.

KEYWORDS: Adaptive immunity, Adoptive cell therapy, Cytokine therapy, Host-directed therapy, Immune checkpoint inhibitors, Immune evasion, Immune modulation, Innate immunity, Monoclonal antibodies, Pathogen interactions.

[*] **Corresponding author Achyut Pandey:** Department of Biotechnology & Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India; Tel: +91-8744091018; E-mail: akp087083@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

INTRODUCTION

Infectious diseases remain a leading cause of morbidity and mortality worldwide, despite advances in antimicrobial drugs. The human immune system is central to the outcome of host-pathogen interactions, mounting innate and adaptive responses to eliminate invading microbes. Pathogens, in turn, have evolved diverse mechanisms to evade or subvert immunity, contributing to disease persistence and severity [1]. Immunotherapy, broadly defined as interventions that harness or modulate the immune system, offers promising strategies to enhance host defense or reduce collateral tissue damage in infections [2]. Vaccines represent the oldest form of immunotherapy, inducing protective immunity against future exposure to pathogens [3]. In recent years, novel immunotherapeutic approaches such as monoclonal antibodies, immune checkpoint inhibitors, cytokine therapies, and adoptive cell transfer have shown potential not only in cancer but also in treating infectious diseases [4], [5]. Likewise, immune modulation *via* vaccines, immunomodulatory drugs, and other host-directed therapies is being explored to improve outcomes across bacterial, viral, fungal, and parasitic infections. This chapter provides a comprehensive overview of innate and adaptive immune responses in host-pathogen interactions, pathogen immune evasion mechanisms, and current immunotherapeutic and immunomodulatory strategies against major classes of human pathogens. We also discuss challenges in targeting the immune response across different pathogens and summarize key clinical trials and outcomes of immune-based interventions in infectious diseases.

Innate Immune Responses in Host-Pathogen Interactions

The innate immune system is the body's first line of defense against invading pathogens. It provides a rapid, nonspecific response within minutes to hours of infection. Key components of innate immunity include physical and chemical barriers (such as skin, mucous membranes, acidic pH, and antimicrobial peptides), phagocytic cells (macrophages and neutrophils), Natural Killer (NK) cells, the complement system, and Pattern Recognition Receptors (PRRs) that detect conserved microbial motifs [6]. Upon pathogen entry, tissue-resident macrophages and dendritic cells recognize Pathogen-Associated Molecular Patterns (PAMPs) *via* PRRs like Toll-Like Receptors (TLRs), NOD-like receptors, and C-type lectins. This triggers intracellular signaling pathways (*e.g.*, NF-κB) that induce proinflammatory cytokines (such as TNF-α, IL-1, IL-6) and type I interferons, thereby promoting an inflammatory response and recruiting additional immune cells to the site of infection [7]. Neutrophils are rapidly recruited from the bloodstream and attack pathogens by phagocytosis, production of reactive oxygen species and proteases, and formation of neutrophil

extracellular traps. Circulating complement proteins become activated *via* the classical, alternative, or lectin pathways and opsonize microbes for phagocytosis or directly lyse certain pathogens through the membrane attack complex [8]. NK cells provide early defense against virus-infected cells or transformed cells by recognizing downregulation of MHC class I molecules or stress-induced ligands on target cells and inducing apoptosis of those targets *via* perforin/granzyme release. Innate immune responses often contain infection during the initial critical hours, preventing pathogen spread. For example, in many viral infections, the rapid production of interferon-α/β creates an antiviral state in neighboring cells and activates NK cells to control virus replication until adaptive immunity is engaged [9]. Importantly, innate immune cells also activate and shape subsequent adaptive immune responses through antigen presentation and cytokine secretion. Dendritic cells that have phagocytosed pathogens migrate to lymph nodes to present antigen peptides (*via* MHC molecules) to T lymphocytes, acting as a bridge between innate and adaptive immunity [10].

Innate immunity is effective but can also cause immunopathology if unregulated. Inflammatory mediators that kill microbes may damage host tissues, and exuberant innate responses contribute to pathology in diseases like sepsis and acute respiratory distress syndrome. For instance, the inducible responses of PRRs, while crucial for pathogen clearance, carry the risk of excessive inflammation and tissue injury [11]. The host therefore employs regulatory mechanisms to temper innate responses, including anti-inflammatory cytokines (IL-10, TGF-β), regulatory macrophages, and constitutive immune factors (such as basal autophagy and restriction factors), that restrain activation to prevent collateral damage. A balanced innate response is thus critical: robust enough to control infection, yet regulated to avoid harming the host. In summary, the innate immune system provides an immediate, broad defense and sets the stage for adaptive immunity through pathogen containment and immune cell priming [12, 13].

Adaptive Immune Responses in Host-Pathogen Interactions

If an infection persists past the initial innate phase, the adaptive immune system is engaged. Adaptive immunity is antigen-specific and has immunologic memory, mounting a stronger and faster response upon re-exposure to the same pathogen. The main players in adaptive immunity are B lymphocytes (humoral immunity) and T lymphocytes (cell-mediated immunity), which recognize specific antigenic epitopes *via* unique receptors generated by gene rearrangement. Activation of adaptive responses typically takes days to weeks after first antigen exposure, as naive B and T cells undergo clonal expansion and differentiation in secondary lymphoid organs [14].

CHAPTER 13

Host-Pathogen Interaction in Emerging Infectious Diseases

Tarun Kumar Upadhyay[1,*] and **Adil Ali**[1]

[1] *Department of Biotechnology, Parul Institute of Applied Sciences and Research and Development Cell, Parul University, Vadodara 391760, Gujarat, India*

Abstract: Host-pathogen interactions are essential to our understanding of infectious diseases. Emerging infectious diseases pose a substantial global health challenge due to their rapid emergence and ability to evade host immune defences. Pathogens employ sophisticated mechanisms to modulate host immune responses, often targeting key immune cells, such as macrophages, to establish infection. Macrophages, as crucial components of the native immune system, are not only troubled by pathogens for survival and replication but also serve as critical mediators of immune defence through phagocytosis and cytokine release. Pathogen-induced apoptosis of host cells further disrupts immune homeostasis, facilitating immune evasion and persistence. Also, biofilm formation by bacterial pathogens increases their resistance to host defences and antimicrobial agents, leading to chronic infections and treatment challenges. Recent studies have highlighted innovative strategies to prevent biofilm formation and target host-pathogen interactions, leading to novel therapeutic development paths. Understanding the molecular mechanisms causing these interactions, with the signalling pathways regulating macrophage responses and apoptosis, is crucial for designing targeted interventions.

Keywords: Apoptosis, Biofilm inhibition, Host-pathogen interaction, Infectious diseases, Macrophage.

INTRODUCTION

A “disease” is any condition that impairs the normal functioning of an organ or system within the body, affects the psyche, or affects the organism as a whole, and is characterised by particular signs and symptoms. Factors that contribute to the damage of organ or system function can be intrinsic or extrinsic [1]. Intrinsic factors arise within the host itself and can be attributed to the genetic makeup of an organism or to conditions that impair the normal functioning of an organ or

[*] **Corresponding author Tarun Kumar Upadhyay:** Department of Biotechnology, Parul Institute of Applied Sciences and Research and Development Cell, Parul University, Vadodara 391760, Gujarat, India; +91-8564879596; E-mail: tarun_bioinfo@yahoo.co.in

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

system. An example is the genetic disorder sickle cell anaemia, characterised by pain and organ damage due to an abnormality in the haemoglobin of RBCs [2]. The abnormality is due to a single base change, in which thymine is replaced by adenine, in a gene encoding one of the chains of the protein haemoglobin. Extrinsic factors are those that enter the host's system when the host comes into contact with agents from the external environment [3]. An example is a mosquito bite from an *Anopheles* mosquito that transmits the malaria parasite *Plasmodium falciparum*. An infectious disease is a condition resulting from the attack of a host by a foreign agent, leading to harm or disruption of the normal functioning of the host's organs or systems [4].

Infectious diseases generally arise from microbes. Their importance stems from the nature and extent of the harm their causative agents inflict on organs or systems when they enter a host [5]. The arrival at the host is generally increased through the mouth, eyes, genital openings, nose, and skin, which serve as the primary entry points. Tissue destruction is mainly caused by the growth of infectious agents and their metabolic effects, whether intracellular or free in body fluids. This is mediated through the expansion and release of toxins or enzymes that interfere with the normal functions of organs and systems [4 - 6]. The circulation of these products might result in the destruction of additional organs or systems, allowing the pathogen to attack them secondarily. The complex body defence system mounts an active defence against infectious agents and removes them from the body [2]. Infectious diseases occur when the body's immune system fails to clear pathogenic infectious agents. Thus, every infectious disease occurs at a point in time within a given population and condition or atmosphere. With a thorough understanding of disease dynamics and routes of spread, methods for fighting, preventing, and controlling diseases are developed [5, 6]. However, few microbes, after apparently being eliminated and entering a resting state, can acquire characteristics that allow them to reinfect either previous or new hosts, frequently in disturbingly increasing proportions [7]. The interaction between host and pathogen is complex, as seen during infections with multicellular parasites such as the cestodes. Every year, millions of people become infected, and many lives are lost. The World Health Organization classified numerous cestode infections as Neglected Tropical Diseases (NTDs) as a call to action to control these infections. The burden of NTDs translates to several million Disability-Adjusted Life Years (DALYs) and costs a few billion dollars in terms of disease and death from these diseases each year [8]. Over millennia, tapeworms coevolved with numerous intermediate and definitive hosts, including humans, thereby giving rise to a complex interplay that has complicated and damaged the host's response to cestode infections. The difficulty of the custodians suggests that they contribute to the ongoing burden of infection worldwide, even though effective treatments are available. The most important pathological changes

during tapeworm infections result from space-occupying metacestodes developing in numerous vital organs of the host, thereby causing serious diseases like cysticercosis, coenurosis, neurocysticercosis, echinococcosis, and sparganosis. In many cases, metacestodes grow from the accretion of Vesicle Fluid (VF) within a space-occupying Vesicle Tissue (VT) [9].

Interactions between Hosts and Pathogens

Host-Pathogen Interactions (HPIs) are complex, dynamic, and the key to understanding infectious diseases. Most research on HPIs has focused on the mechanisms by which microbes attack hosts, overcome host defences, and proliferate within hosts. Researchers also explore how hosts defend themselves against microbes, such as immune responses induced as a reaction to attackers [10]. Pathogen invasion begins with its diffusion into the host. Different methods of entry or cascades can be used, such as the process of entering the surface of host cells, mucosal membranes, or natural cavities [11, 12]. When microbes enter hosts, they interact with host cells to survive and proliferate by targeting multiple host targets through specific mechanisms. For example, the envelope of viral pathogens fuses with HCM when infecting host cells [13]. Bacteria, fungi, or nematodes use specialised excretion systems to deliver effectors into host cells, affecting several biological and biochemical processes in the hosts [14 - 16]. Fungi can also use effectors on their hyphal surfaces to interact with receptors on host cells, which then triggers endocytosis or the cellular uptake of pathogens [17]. Pathogens can interact with the HIS by inducing and inhibiting immune responses. Immune responses of hosts arise in a well-ordered manner, first triggered by preserved pathogen molecules recognised by specific host receptors [18]. Then, resistance signals are transduced to the cell surface or cytoplasm through a signal cascade. Finally, hosts detect resistance signals and trigger defence mechanisms to fight microbes [19]. Pathogens can target resistance mechanisms, which can escape host ligand recognition by modifying or shielding conserved molecules [20 - 21]. To overcome resistance mechanisms, invaders can inhibit the function or degrade proteins or signalling molecules involved in several defence responses, suppress microbial growth, or directly remove pathogens [22, 23]. Fig. (**1**) illustrates different mechanisms of host-pathogen interaction.

Amplification of numbers is crucial for successful pathogen invasion. This process is often accomplished by operating the host cellular machinery in one way or another. Acellular pathogens such as viruses, viroids, and prions mostly depend on either the nucleic acid or host protein synthesis cascade for their replication [24, 25]. Cellular pathogens like fungi, bacteria, protozoa, and nematodes tend to extract nutrients from their hosts while reproducing using their own cellular

CHAPTER 14

Artificial Intelligence in Host-Pathogen Interaction

Shreya Mishra[1], Sacheen Kumar[2] and **Achyut Pandey[2,*]**

[1] *Department of Computer Science and Engineering, Indian Institute of Information Technology, Bhagalpur 813210, Bihar, India*

[2] *Department of Biotechnology & Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India*

Abstract: The integration of Artificial Intelligence (AI) into host-pathogen interaction research has ushered in a transformative era in infectious disease understanding, surveillance, and intervention. This chapter explores how AI technologies, from machine learning and deep learning to graph-based algorithms, reinforcement learning, and federated learning, are revolutionizing the study of viral and bacterial infections. By enabling precise modeling of protein-protein interactions, drug discovery, diagnostics, vaccine development, and outbreak forecasting, AI is enhancing our capacity to predict pathogen behavior, understand immune responses, and tailor treatment strategies. The chapter delves into specific AI applications such as generative adversarial networks for data augmentation, AI-guided antimicrobial resistance prediction, and vector-borne disease modeling. It also examines the deployment of AI in public health surveillance systems and personalized medicine. Despite its promise, the chapter highlights challenges like data privacy, model interpretability, bias, and ethical concerns. Future directions include integration with quantum computing, synthetic biology, and multimodal data to further decode host-pathogen complexity. Overall, AI stands as a critical tool in the modern infectious disease toolkit, driving rapid advancements in global health research and response strategies.

Keywords: Artificial intelligence, Antimicrobial resistance, Drug discovery, Epidemiological surveillance, Federated learning, Generative adversarial networks, Graph neural networks, Machine learning, Network analysis, Personalized medicine.

INTRODUCTION

Artificial Intelligence (AI) has progressively transformed the study of infectious diseases over the past decades. Early milestones in the field date back to the 1970s, when rule-based expert systems like MYCIN, an early rule-based AI prog-

[*] **Corresponding author Achyut Pandey:** Department of Biotechnology & Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida 203201, Uttar Pradesh, India; Tel: +91-8744091018; E-mail: akp087083@gmail.com

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

ram developed at Stanford to diagnose bacterial infections and recommend antibiotic therapy, were developed to assist physicians in identifying bacteria and recommending antibiotics for blood infections [1]. These pioneering systems demonstrated the potential of computational reasoning in infectious disease management, even if their uptake in clinical practice was limited by the technology of the time. Through the 1980s and 1990s, AI in medicine evolved through periods of optimism and setback, but by the early 21st century, the convergence of big data from genomics and electronic health records with improved machine learning algorithms reignited progress in AI applications for infectious diseases. Over the years, AI techniques moved from logical rule-based approaches to data-driven machine learning and, most recently, to deep learning models capable of uncovering complex patterns [2].

Major public health crises have often spurred advances in AI for epidemiology. For example, the 2002–2003 SARS outbreak and the 2009 H1N1 influenza pandemic prompted the development of digital disease surveillance platforms (*e.g.*, HealthMap and ProMED) that aggregate online reports to detect emerging threats [3], [4], [5]. By mining news and social media, these early systems provided a blueprint for how AI-driven analytics could give early warnings. Indeed, by 2019, the internet-based HealthMap system had automatically flagged a "cluster of pneumonia of unknown cause" in Wuhan on December 30, 2019, just days after the first COVID-19 cases were reported. This exemplified how AI surveillance could alert authorities to novel outbreaks faster than traditional channels [6]. The COVID-19 pandemic of 2020 dramatically accelerated the adoption of AI in host-pathogen research and response. During COVID-19, AI proved critical in multiple domains, from rapid genome sequencing and variant tracking to drug repurposing and vaccine development. In diagnostic radiology, for instance, deep learning systems were deployed to assist in identifying COVID-19 pneumonia on chest X-rays and CT scans when human resources were overwhelmed. AI models also helped monitor epidemiological trends, integrating mobility data and case reports to forecast outbreak dynamics [7].

Pandemics have therefore catalyzed AI innovation. The urgency and scale of COVID-19 led to unprecedented global data sharing and cross-disciplinary collaboration, allowing machine learning models to be trained on massive datasets. Governments and health agencies established specialized AI task forces (for example, the US CDC's Center for Forecasting and Outbreak Analytics and the WHO's Pandemic Hub) to incorporate AI into surveillance programs. Today, AI is recognized as an essential component in our arsenal against infectious diseases. From identifying subtle molecular interactions between hosts and pathogens to scanning population-level data for outbreak signals, AI technologies are helping researchers and clinicians make sense of the complexity in host-

pathogen systems [8]. In the sections that follow, we provide a comprehensive overview of how various AI techniques are applied to host-pathogen interactions, discuss concrete applications in research and public health, explore new frontiers like antimicrobial resistance and One Health, and consider the challenges and future directions of this rapidly evolving field.

AI Techniques in Host-Pathogen Interactions

Advances in computer science have led to a toolkit of AI techniques tailored to problems in host-pathogen biology. Key methods include graph-based algorithms to analyze biological networks, deep learning approaches (including generative models) to handle complex data, reinforcement learning for sequential decision-making, and privacy-preserving machine learning to leverage distributed data [9]. Below, we delve into several prominent AI techniques and how they are applied to host-pathogen interactions (Table **1**).

Table 1. AI techniques and their typical uses.

AI technique/family	Key idea (1 line)	Typical host–pathogen applications
Graph neural networks/graph algorithms	Learn from node–edge structure in networks	Predict host–pathogen PPIs, identify hub/bottleneck host targets, and integrate knowledge graphs
Deep learning (CNNs, RNNs, transformers)	Multi-layer feature learning from complex data	Imaging diagnostics (X-ray/CT, microscopy), genomic/sequence modelling, language models for literature mining
Generative models (GANs, VAEs)	Generate realistic synthetic data or sequences	Data augmentation for imaging/omics, synthetic genomes/microbiomes, antigen/protein design
Reinforcement learning	Trial-and-error optimisation via rewards	De novo small-molecule design, optimisation of testing strategies and treatment policies
Classical ML (RF, SVM, gradient boosting)	Supervised pattern discovery from tabular data	AMR prediction from genomes, severity risk scores, biomarker panels, outbreak forecasting
Federated/privacy-preserving learning	Train jointly without pooling raw data	Multi-hospital prognostic models, global surveillance across regions, cross-silo EHR models

Graph-Based AI for Protein-Protein Interactions

Graph-based AI has emerged as a powerful approach to model the intricate networks of interactions between hosts and pathogens. In a graph representation,

CHAPTER 15

Future Directions in Host Pathogen Research

Kajal[1] and **Amit K. Gupta**[2,*]

[1] *School of Commerce, Galgotias University, Greater Noida 203201, Uttar Pradesh, India*

[2] *Mouse Cancer Genetics Program, National Cancer Institute, NIH, Frederick 21702, Maryland, United States of America*

Abstract: A vital part of understanding infectious diseases and their effects on global health is host-pathogen research. In the realm of multilevel population dynamics, the study of infectious diseases is a well-established area with significant theoretical and practical research. Nonetheless, the interactions between hosts and pathogens, along with the dynamics within a single infected host-pathogen system, remain a largely unexplored research avenue. This chapter examines potential paths forward in this ever-evolving field, emphasizing novel strategies and new challenges. The study of host-pathogen interactions is undergoing a revolution because of developments in genomics, proteomics, and artificial intelligence. These developments are offering fresh perspectives on pathogen evasion tactics and immune responses. Next-generation vaccines, host-directed therapeutics, and targeted drug development are examples of innovative therapeutic approaches that are opening the door to customized care. Innovative models such as organoids and 3D cultures, in conjunction with microbiome-targeted strategies, are revolutionizing experimental techniques. Furthermore, the combination of One Health and global health programs emphasizes the significance of teamwork in addressing new infectious risks. Additionally, investigations spanning the molecular and cellular levels and extending to the host and population levels could greatly enhance our understanding of host–pathogen dynamics and evolution. By discussing the intricacies of coevolution and the impact of climate change, this chapter emphasizes the creative and multidisciplinary approaches required to advance host-pathogen research in the coming decades.

Keywords: Artificial intelligence, Co-evolution, 3D cultures, Host pathogen, Host-directed therapeutics, Infectious disease, Immune responses, Targeted drug development, Multidisciplinary approach, Next generation vaccines.

INTRODUCTION

The study of host-pathogen interactions is essential to understanding the mechanisms behind infectious diseases and their impact on global health. These

* **Corresponding author Amit K. Gupta:** Mouse Cancer Genetics Program, National Cancer Institute, NIH, Frederick 21702, Maryland, United States of America; E-mail: amit.gupta@nih.gov

Shruti Mishra, Rupesh Chaturvedi, & Achyut Pandey (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

interactions, which can range from self-limited ailments to persistent, life-threatening issues, are essential in defining the course of infections. [1]. The dynamic interplay between the host immune system and the invading infections shapes them. The intricate molecular and cellular relationships between infections and hosts are still being thoroughly investigated, despite the fact that the epidemiology and population dynamics of infectious diseases have been well examined. Understanding these interactions is crucial for developing effective treatments and vaccines, as well as for understanding how infections evolve over time as the host immune system adapts. Recent advances in genomics, proteomics, and artificial intelligence have revolutionized our ability to study host-pathogen interactions in unprecedented detail [2]. These technological developments have enabled novel approaches to understanding pathogen evasion strategies, host immune responses, and the biological basis of disease pathogenesis. A comparative overview of experimental models is provided in Table **1**. Furthermore, in addition to microbiome-targeted methods, the development of novel experimental models, such as organoids and three-dimensional cell cultures, has opened p new avenues for studying host-pathogen interactions in more physiologically relevant environments. [3]. The growing recognition of the interdependencies among environmental, animal, and human health led to the development of the One Health concept, which highlights the importance of a collaborative, interdisciplinary approach for treating infectious diseases. Given the ongoing emergence of novel diseases and the acceleration of environmental changes driven by climate change, which may affect disease transmission, a comprehensive understanding of host-pathogen dynamics is more crucial than ever. [4]. With a focus on innovative methods and emerging issues, this review aims to assess the current status of host-pathogen research. We will discuss how our understanding of infectious diseases is evolving due to new experimental models and recent technological advancements. The broader implications of host-pathogen research will also be examined, including the role of coevolution, the consequences of climate change, and the importance of global health initiatives in addressing the evolving threats posed by infectious diseases [5]. The ultimate goal of this study is to provide a comprehensive overview of the directions that host-pathogen research will take in the coming decades, emphasizing the need for interdisciplinary approaches to handle the complexity of infectious diseases.

INTEGRATION OF MULTI-OMICS APPROACHES

Understanding infectious diseases is being revolutionized by multi-omics approaches that capture the complex interactions between pathogens and hosts across multiple biological levels. By using this all-encompassing method, scientists can investigate how viruses modify the genetic, cellular, and metabolic

processes of their hosts in order to establish infection and improve their chances of survival. [6]. By integrating transcriptomics, proteomics, metabolomics, and genomics, scientists may identify genetic predispositions that influence an individual's susceptibility or resistance to infections, allowing for early identification and treatment. Transcriptome analysis provides early signs of infection, including immune response activation, inflammatory signaling, and cell stress responses, by demonstrating the host's reaction at the level of gene expression. [7]. These indicators can alert healthcare providers to the onset of an infection, frequently before overt clinical symptoms appear. Faster identification of the infecting agent and more accurate diagnosis are made possible by pathogen-specific RNA signatures, such as the expression of bacterial virulence genes or viral replication markers. This understanding is extended by proteomics, which reveals functional changes at the protein level [8]. The way a disease develops can be immediately revealed by changes in proteins, which are the functional molecules that perform biological processes. For instance, pathogen-produced proteins, including enzymes, poisons, and structural components, can serve as indicators of infection, while cytokines and chemokines can indicate when the host immune response is triggered. More accurate infection surveillance and diagnosis are made possible by the analysis of proteins generated or changed during infection [9]. As illustrated in Fig. (**1**), microbial composition and function dynamically influence host responses and health outcomes. Metabolomics provides an additional important layer of information by monitoring the host's metabolic changes throughout infection. Often, pathogens alter their hosts' metabolisms to increase their chances of survival and growth. These metabolic alterations can be detected by researchers to identify biomarkers for early detection, severity assessment, and illness monitoring. The use of multi-omics approaches is transforming clinical practice in the diagnosis and treatment of illness [10]. By identifying unique biomarkers for different stages of infection, clinicians can make better decisions regarding diagnosis, prognosis, and therapies. Proteomic and metabolomic biomarkers help monitor the progression of an illness and the effectiveness of therapeutic interventions, whereas transcriptome and genomic biomarkers can detect infections at an early stage. Finding unique molecular profiles for each patient might lead to customized treatment regimens that make use of the patient's unique genetic and molecular characteristics to provide more precise and targeted care [11]. When these technologies are combined, disease surveillance might be dramatically changed, especially when it comes to newly emerging infectious diseases. By tracing genetic markers across populations, researchers may detect new strains, track the spread of illnesses, and predict epidemics before they become widespread. Early detection may become more accessible using point-of-care diagnostic tools based on multi-omics data, especially in settings with little resources [12]. Moreover, the application of

SUBJECT INDEX

A

Acquired immunodeficiency syndrome 108, 129, 135, 140, 194, 281
Acute respiratory distress syndrome 149, 164, 265, 282
Adaptive 1, 2, 3, 4, 5, 6, 7, 13, 14, 15, 21, 24, 27, 39, 40, 43, 45, 60, 73, 156, 157, 162, 258, 263, 264, 265, 267
  immune responses 1, 4, 39, 43, 45, 156, 162, 258, 263, 264, 265, 267
  immunity 1, 2, 3, 5, 6, 7, 13, 14, 15, 21, 24, 27, 157, 265, 267
  responses 40, 60, 73, 264, 265, 267
Antibody-dependent cellular cytotoxicity (ADCC) 23, 277
Anti-inflammatory cytokines 29, 46, 68, 150, 157, 161, 185, 187, 190, 265
Antibiotic resistance 197, 199, 216, 219, 223, 227, 228, 229, 374, 381, 383
Antigen 2, 3, 6, 12, 14, 15, 25, 26, 39, 40, 61, 118, 163, 167, 183, 184, 256, 266, 270, 271
  presentation 2, 3, 6, 12, 14, 15, 26, 39, 40, 183, 184, 270, 271
  presenting cells (APCs) 14, 25, 26, 61, 118, 163, 167, 256, 266
Antigenic variation 1, 2, 8, 9, 10, 44, 45, 57, 66, 268, 269, 270, 271, 273, 274
Antimicrobial 20, 23, 24, 50, 72, 182, 183, 194, 195, 197, 214, 215, 216, 221, 222, 223, 224, 229, 230, 239, 312, 330, 351, 352, 353, 354, 370, 378, 382
  peptides (AMPs) 20, 23, 24, 182, 183, 194, 195, 197, 214, 221, 222, 223, 224, 229, 353
  resistance (AMR) 50, 72, 214, 215, 216, 230, 239, 312, 330, 351, 352, 354, 370, 378, 382
Autoimmune diseases 7, 149, 150, 156, 163, 166, 167, 168, 169, 275, 282
Autoimmunity 2, 7, 27, 28, 167, 168, 169, 184, 185, 187, 188, 290, 291

B

Bacteriophages 201, 238, 239, 353
Biofilms 55, 58, 201, 202, 222, 223, 229, 230, 269, 272, 305, 307, 308
Bioactive glass (BG) 229, 234, 236

C

C-reactive protein (CRP) 150, 164, 340, 342
Candida albicans 2, 101, 107, 196, 272, 318
Carboxymethyl cellulose (CMC) 234, 235, 236
Cell-mediated immunity 6, 20, 25, 118, 246, 265, 267, 269
Chronic 30, 39, 40, 149, 150, 151, 154, 155, 156, 158, 165, 166, 169, 186, 188, 190, 281, 282
  granulomatous disease (CGD) 30, 281, 282
  inflammation 39, 40, 149, 150, 151, 154, 155, 156, 158, 165, 166, 169, 186, 188, 190
Clostridioides difficile infection (CDI) 182, 191, 192, 276, 289
Clostridium difficile 69, 193, 372, 373
Coevolution 127, 128, 129, 130, 133, 136, 366, 367, 380, 381
Colonization resistance 69, 71, 73, 178, 181, 182, 183, 190, 191, 197,

All rights reserved-© 2026 Bentham Science Publishers

199, 200, 289
Complement system 1, 5, 20, 21, 26, 27, 61, 161, 264
Convolutional neural networks 332, 335, 341
Cytokine storm (CS) 32, 149, 156, 163, 164, 237, 269, 282, 283, 290, 339, 340
Cytotoxic T-lymphocytes (CTLs) 137, 247, 255, 266, 267, 269, 270, 271, 310

D

Damage-associated molecular patterns (DAMPs) 27, 28, 150, 153, 160, 162, 163, 167, 376
Dendritic cells (DCs) 4, 14, 22, 23, 27, 28, 29, 157, 158, 184, 185, 187, 246, 249, 250, 252, 256, 257, 264, 271, 272, 274
Dermatophytes 102, 103, 104, 105
DNA vaccines 255, 256, 287
Dysbiosis 4, 69, 70, 71, 175, 176, 184, 185, 186, 187, 188, 190, 191, 195, 198

E

Epithelial-mesenchymal transition 166
Epstein-barr virus (EBV) 87, 140, 270, 271, 284, 285, 305
Erythrocyte sedimentation rate 150, 159
Escherichia coli 2, 57, 62, 64, 66, 192, 193, 195, 198, 199, 226, 235, 237, 247, 251, 256, 312, 315, 317, 334, 353

F

Faecal microbiota transplantation 71, 175, 179, 182, 188, 191, 200, 202, 203, 204, 289, 372, 373
Federated learning (FL) 330, 332, 336, 358

G

Gastrointestinal tract 9, 23, 49, 57, 60, 140, 176, 197
Generative adversarial networks 330, 332, 335, 345
Gut 3, 68, 70, 176, 180, 181, 184, 185, 186, 187, 192, 193, 195, 197, 200
  associated lymphoid tissues (GALT) 3, 184, 185, 186
  microbiome 68, 180, 185, 186, 192, 193, 195, 197, 200
  microbiota 70, 176, 181, 187, 193, 195

H

Helicobacter pylori 59, 63, 68, 188, 198, 304, 306, 307
Helminths 2, 7, 12, 13, 100, 112, 115, 116, 117, 118, 198, 273, 274
Hepatitis 10, 11, 87, 89, 94, 132, 133, 134, 136, 251, 253, 267, 270, 271, 279, 280, 285, 286, 289
  B virus (HBV) 10, 11, 94, 132, 133, 134, 136, 251, 253, 267, 270, 271, 280, 285, 286
  C virus (HCV) 87, 89, 136, 251, 279, 280, 289
Hepatocellular carcinoma (HCC) 132, 134
Herpes simplex virus (HSV) 87, 89, 127, 139, 270, 306
Human 11, 83, 88, 89, 92, 94, 107, 127, 128, 129, 130, 131, 134, 135, 136, 137, 142, 168, 194, 195, 231, 248, 251, 252, 253, 267, 270, 271, 278, 281, 284, 285, 286, 287, 291, 318, 319, 340, 344, 345, 350, 351, 356, 375
  immunodeficiency virus (HIV) 83, 88, 89, 94, 107, 127, 128, 129, 130, 131, 134, 135, 136, 137, 142, 194, 195, 231, 248, 252, 267, 270, 271, 278, 281, 284, 285, 286, 287, 291, 318, 319, 350, 351, 375
  leukocyte antigen (HLA) 134, 137, 168, 291, 340, 345

papillomavirus (HPV) 11, 92, 136, 251, 253, 287, 344, 356
Host-directed therapies (HDTs) 39, 50, 51, 82, 263, 264, 286, 288, 289, 290, 292, 314, 366, 374, 375, 376, 377, 383

I

Immunoglobulin 6, 14, 153, 154, 183, 184, 186, 227, 266, 269, 273, 274, 315
A (IgA) 6, 14, 183, 184, 186, 266, 269, 273
G (IgG) 6, 14, 153, 154, 227, 266, 269, 274, 315
Immune 2, 8, 9, 40, 41, 43, 44, 45, 46, 48, 50, 51, 62, 81, 137, 169, 190, 203, 263, 264, 267, 268, 269, 270, 271, 273, 274, 275, 278, 279, 280, 287, 288, 290, 291, 306, 309, 367, 374, 376
checkpoint inhibitors (ICIs) 169, 190, 203, 263, 264, 275, 278, 279, 280, 288, 290, 291, 376
evasion 2, 8, 9, 40, 41, 43, 44, 45, 46, 48, 50, 51, 62, 81, 137, 190, 264, 267, 268, 269, 270, 271, 273, 274, 275, 287, 306, 309, 367, 374
Inflammatory bowel disease (IBD) 4, 28, 30, 150, 158, 166, 181, 182, 183, 184, 190, 191, 201, 202
Interferons (IFNs) 2, 5, 23, 27, 28, 29, 30, 133, 139, 158, 162, 249, 263, 264, 265, 267, 269, 270, 280, 281, 283, 307, 319, 340, 344
Interleukins (ILs) 5, 27, 28, 29, 30, 46, 61, 67, 68, 118, 130, 149, 150, 152, 153, 155, 156, 157, 158, 159, 161, 163, 164, 165, 166, 167, 169, 183, 184, 185, 187, 188, 190, 196, 264, 265, 266, 272, 274, 280, 281, 282, 283, 305, 306, 317, 318, 340, 341, 343, 350

K

Kaposi sarcoma associated herpesvirus (KSHV) 126, 128, 129, 130, 131, 136

L

Leishmania 113, 274, 279, 306
Lipopolysaccharides (LPS) 5, 27, 67, 160, 184, 185, 189, 235, 306, 310

M

Major histocompatibility complex 4, 6, 26, 29, 43, 44, 45, 61, 15, 168, 249, 250, 255, 256, 265, 266, 270, 271, 274, 285
Monoclonal antibodies (mAbs) 15, 263, 264, 275, 276, 277, 278, 288, 290, 292, 315, 376, 377
Methicillin-resistant *Staphylococcus aureus* (MRSA) 83, 200, 222, 223, 226, 315
Microbiome 68, 71, 142, 175, 176, 178, 179, 180, 182, 183, 185, 186, 187, 188, 189, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 335, 366, 372, 373, 377
Mycobacterium tuberculosis (mTB) 59, 62, 64, 68, 217, 266, 267, 268, 270, 287, 288, 290, 305, 306, 307, 310, 311, 313, 317, 338, 341

N

Natural 4, 13, 14, 21, 23, 60, 61, 157, 264, 265, 270, 271, 280, 283, 285, 286, 342, 343, 345, 347, 349
killer cells (NK cells) 4, 13, 14, 21, 23, 60, 61, 157, 264, 265, 270, 271, 280, 283, 285, 286
language processing (NLP) 342, 343, 345, 347, 349
Next-generation sequencing (NGS) 72, 378

Nod-like receptors (NLRs) 5, 27, 28, 32, 160, 161, 163, 165, 306, 307

O

Organoids 366, 367, 371, 372, 373, 383

P

Pathogen-associated molecular patterns (PAMPs) 3, 5, 20, 21, 27, 28, 60, 67, 150, 160, 162, 163, 177, 264, 268, 272, 273, 376
Pattern recognition receptors (PRRs) 3, 5, 20, 27, 28, 32, 42, 45, 60, 67, 68, 69, 150, 160, 162, 165, 177, 182, 183, 184, 190, 264, 269, 271, 306, 311
Phagocytosis 14, 15, 26, 60, 61, 62, 64, 153, 154, 187, 264, 265, 266, 268, 269, 272, 277, 305
Plasmodium falciparum 12, 113, 114, 115, 251, 268, 273, 302, 304
Polymerase chain reaction (PCR) 110, 254, 343
Prebiotics 71, 175, 183, 188, 190, 196, 200, 202, 289, 372
Probiotics 179, 180, 186, 188, 190, 192, 193, 194, 196, 200, 201, 202, 203, 204, 372, 373, 377
Programmed cell death 1 (PD-1) 7, 44, 47, 166, 263, 267, 271, 278, 279, 280, 290, 376
Protein-protein interactions (PPIs) 321, 330, 332, 333, 344, 355
Pseudomonas aeruginosa 65, 197, 217, 223, 269, 305, 307, 315

Q

Quorum sensing (QS) 197, 223, 307, 316

R

Reactive oxygen species (ROS) 46, 60, 153, 154, 161, 165, 225, 237, 264, 268, 272, 281, 288
Reinforcement learning (RL) 330, 332, 334, 335, 344, 347, 350, 359
Rheumatoid arthritis (RA) 7, 30, 150, 155, 158, 167, 168, 169, 185, 190, 317, 344
Rig-i-like receptors (RLRs) 27, 28, 162, 270

S

Salmonella enterica 9, 42, 59, 63, 64, 68, 193, 195, 197, 198, 199, 266, 268, 269, 281, 305
SARS-CoV-2 192, 223, 256, 257, 269, 276, 318, 319, 333, 338, 344, 345, 348, 355, 371, 373
Schistosoma 2, 9, 12, 116, 117, 118, 119, 127, 274, 275, 307
Short-chain fatty acids (SCFAs) 4, 70, 175, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 196, 198, 202
Staphylococcus aureus 2, 57, 58, 62, 63, 65, 67, 73, 83, 194, 195, 197, 198, 200, 216, 222, 227, 228, 231, 235, 236, 237, 269, 277, 305, 315, 316, 317, 318
Stimulator of interferon genes 27, 162, 163
Streptococcus pneumoniae 62, 64, 74, 192, 197, 266, 267, 268, 269, 282, 305
Systemic lupus erythematosus 167, 169

T

T- 4, 6, 7, 13, 17, 26, 42, 58, 66, 81, 106, 118, 137, 157, 166, 168, 175, 182, 183, 184, 185, 186, 187, 189, 190, 192, 196, 198, 266, 267, 272, 273, 274, 279, 284, 287, 290, 318, 339, 376
  cell receptor (TCR) 26, 42, 58, 66, 81, 137, 284, 318, 339
  helper 17 (Th17) 4, 6, 7, 183, 184, 186, 196, 266, 273, 274
  helper 1 (Th1) 6, 7, 118, 157, 184, 186, 266, 267, 272, 273, 274, 279, 287, 290
  helper 2 (Th2) 6, 7, 13, 106, 118, 184, 186, 190, 266, 272, 274

regulatory cells (Tregs) 6, 166, 168, 175, 182, 183, 184, 185, 186, 187, 189, 192, 196, 198, 274, 376
Toll-like receptors (TLRs) 5, 27, 28, 29, 32, 67, 68, 160, 162, 163, 182, 183, 184, 185, 186, 198, 249, 264, 283, 306, 307
Toxoplasma gondii 100, 113, 273, 285, 306, 310
Tumor necrosis factor-alpha (TNF-α) 61, 67, 158, 169, 271, 282, 310, 340

U

Urinary tract infections (UTIs) 66, 109, 192, 199, 315, 352

V

Virus-like particles (VLPs) 229, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 258, 259, 378

Z

Zoonotic diseases 112, 138, 310, 338, 359, 379, 380, 383



Shruti Mishra

Dr. Shruti Mishra is an Assistant Professor in the Department of Biotechnology & Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida, Uttar Pradesh, India. Her research focuses on host-pathogen dynamics, innate and adaptive immune mechanisms, and viral and bacterial evasion strategies. She has published extensively in peer-reviewed scientific journals and has contributed significantly to understanding host counter-evasion mechanisms and vaccine development. As a lead editor, Dr. Mishra brings a process-oriented and integrative approach to translational research in host-directed therapeutics and infectious disease management.



Rupesh Chaturvedi

Prof. Rupesh Chaturvedi is a Professor at the School of Biotechnology, Jawaharlal Nehru University (JNU), New Delhi, India. With decades of academic and research leadership, his primary work centers on immunobiology, cellular signaling, host-defense mechanisms, and pathogen-host interactions in chronic and infectious diseases. Prof. Chaturvedi has authored more than a hundred publication in prestigious international journals. His expertise encompasses dissecting complex molecular crosstalk between host immune networks and microbial pathogens, guiding rational approaches for therapeutic intervention, drug target discovery, and immunomodulatory therapies.



Achyut Pandey

Dr. Achyut Pandey serves as a Assistant Professor at the School of Biosciences and Technology, Galgotias University, Greater Noida, Uttar Pradesh, India. His interdisciplinary research spans immunology, immunotherapy, host-pathogen network modeling, and the application of modern technologies—including artificial intelligence and computational biology—in infectious disease research. Dr. Pandey has contributed widely to scientific literature on immune modulation, multi-omics integration, and novel antimicrobial delivery systems. He is dedicated to advancing precision medicine and host-directed immunotherapies to combat emerging pathogens and antimicrobial resistance.